Advertisement

Drug Safety

, Volume 16, Issue 3, pp 180–204 | Cite as

Drug-Induced Movement Disorders

  • Félix Javier Jiménez-Jiménez
  • Pedro José García-Ruiz
  • José Antonio Molina
Review Article Pharmacoepidemiology

Summary

Parkinsonism, tremor, chorea-ballismus, dystonia, tardive dyskinesia, myoclonus, tics and akathisia can be induced by many drugs. The drugs that are most frequently implicated in movement disorders are antipsychotics, calcium antagonists, orthopramides and substituted benzamides (e.g. metoclopramide, sulpiride, clebopride, domperidone), CNS stimulants, antidepressants, anticonvulsants, antiparkinsonian drugs and lithium. It is possible for a single drug to induce 2 or more types of movement disorders in the same patient. Movement disorders are not always reversible after drug withdrawal.

Keywords

Clozapine Dystonia Tardive Dyskinesia Clin Psychiatry Buspirone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Martí-Massó JF, Carrera N, Urtasun M. Newer drugs inducing parkinsonism [abstract]. 9th International Symposium on Parkinson’s disease: 1988 Jun 5-9; Jerusalem, Israel: 137Google Scholar
  2. 2.
    Martí-Massó JF, Carrera N, Urtasun M. Drug-induced parkinsonism: a growing list [letter]. Mov Disord 1993; 8: 125PubMedGoogle Scholar
  3. 3.
    Gershanik OS. Drug-induced movement disorders. Curr Opin Neurol Neurosurg 1993; 6: 369–76PubMedGoogle Scholar
  4. 4.
    Gershanik OS. Drug-induced parkinsonism in the aged: recognition and prevention. Drugs Aging 1994; 5: 127–32PubMedGoogle Scholar
  5. 5.
    Pérez-Gilabert Y, Mateo D, Giménez-Roldán S. Actividad asistencial en una consulta hospitalaria especializada en en-fermedad de Parkinson y transtornos del movimiento: un estudio prospectivo durante años. Neurología (Spain) 1994; 9: 317–23Google Scholar
  6. 6.
    Llau ME, Nguyen L, Senard JM, et al. Syndromes parkinsoniens d’origine médicamenteuse: expérience d’un centre régional de pharmacovigilance sur dix ans. Rev Neurol (Paris) 1994; 150: 757–76Google Scholar
  7. 7.
    Martí-Massó JF, Poza JJ. Parkinsonismo inducido o agravado por fármacos: características clínicas y evolutión histórica de los fármacos implicados. Neurología (Spain) 1996; 11: 10–5Google Scholar
  8. 8.
    Jiménez-Jiménez FJ, Ortí-Pareja M, Ayuso-Peralta L, et al. Drug-induced parkinsonism in a movement disorders unit. A four-year survey. Parkinsonism Rel Disord 1996; 2: 145–9Google Scholar
  9. 9.
    Morgante L, Rocca WA, Di Rosa AE, et al. Prevalence of parkinson’s disease and other types of parkinsonism: a door-to-door survey in three Sicilian municipalities. The Sicilian neuro-epidemiologic study (SNES) group. Neurology 1992; 42: 1901–7PubMedGoogle Scholar
  10. 10.
    Trenkwalder C, Schwarz J, Gebhard J, et al. Starnberg trial on epidemiology of parkinsonism and hypertension in the elderly. Prevalence of parkinson’s disease and related disorders assessed by a door-to-door survey of inhabitants older than 65 years. Arch Neurol 1995; 52: 1017–22PubMedGoogle Scholar
  11. 11.
    Hubble JP. Drug-induced parkinsonism. In: Stern MB, Koller WC, editors. Parkinsonian syndromes. New York: Marcel Dekker Inc., 1993: 111–22Google Scholar
  12. 12.
    Ayd Jr FJ. A survey of drug-induced extrapyramidal reactions. JAMA 1961; 175: 1054–60PubMedGoogle Scholar
  13. 13.
    Murphy JE, Stewart RB. Efficacy of antiparkinsonian agents in preventing antipsychotic-induced extrapyramidal symptoms. Am J Hosp Pharm 1979; 36: 641–4PubMedGoogle Scholar
  14. 14.
    Binder RL, Kazamatsuri H, Nishimura T, et al. Tardive dyskinesia and neuroleptic-induced parkinsonism in Japan. Am J Psychiatry 1987; 144: 1494–6PubMedGoogle Scholar
  15. 15.
    Miller LG, Jankovic J. Neurologic approach to drug-induced movement disorders: a study of 125 patients. South Med J 1990; 8: 525–32Google Scholar
  16. 16.
    Ganzini L, Heintz R, Hoffman WF, et al. Acute extrapyramidal syndromes in neuroleptic-treated elders: a pilot study. J Geriatr Psychiatry Neurol 1991; 4: 222–5PubMedGoogle Scholar
  17. 17.
    Avorn J, Bohn RL, Mogun H, et al. Neuroleptic drug exposure and treatment of parkinsonism in the elderly: a case-control study. Am J Med 1995; 99: 48–54PubMedGoogle Scholar
  18. 18.
    Martí-Massö JF, Carrera N, de la Puente E. Posible parkinsonismo por cinaricina. Med Clin (Barc) 1985; 85: 614–6Google Scholar
  19. 19.
    Chouza C, Scarameli A, Caamaño JL, et al. Parkinsonism, tardive dyskinesia, akathisia, and depression-induced by flunarizine. Lancet 1986; I: 1300–4Google Scholar
  20. 20.
    Di Rosa AE, Morgante L, Meduri M, et al. Parkinson-like side effects during prolonged treatment with flunarizine. Funct Neurol 1987; 2: 47–50PubMedGoogle Scholar
  21. 21.
    Micheli F, Pardal MF, Gatto M, et al. Flunarizine- and cinnarizine-induced extrapyramidal reactions. Neurology 1987; 7: 881–4Google Scholar
  22. 22.
    De Michele G, Filla A, Coppola N, et al. Extrapyramidal side-effects of flunarizine. Acta Neurol [Quad] (Napoli) 1987; 9: 230–3Google Scholar
  23. 23.
    Fernández-Pardal M, Fernández-Pardal J, Micheli F. Aggravation of parkinson’s disease by cinnarizine [letter]. J Neurol Neurosurg Psychiatry 1988; 51: 158–9PubMedGoogle Scholar
  24. 24.
    Moretti A, Lucantoni C. Flunarizine-induced parkinsonism: clinical report. Ital J Neurol Sci 1988; 9: 295–7PubMedGoogle Scholar
  25. 25.
    Capellà D, Laporte JR, Castel JM, et al. Parkinsonism, tremor, and depression-induced by cinnarizine and flunarizine [letter]. BMJ 1988; 297: 722–3PubMedGoogle Scholar
  26. 26.
    Benvenutti F, Baroni A, Bandinelli S, et al. Flunarizine-induced parkinsonism in the elderly. J Clin Pharmacol 1988; 28: 600–8Google Scholar
  27. 27.
    Kuzuhara S, Kohara N, Ohkawa Y, et al. Parkinsonism, depression and akathisia-induced by flunarizine, a calcium entry blockade. Report of 31 cases. Rinsho Shinkeigaku 1989; 29: 681–6PubMedGoogle Scholar
  28. 28.
    Micheli FE, Fernández Pardal M, Giannaula R, et al. Movement disorders and depression due to flunarizine and cinnarizine. Mov Disord 1989; 4: 139–46PubMedGoogle Scholar
  29. 29.
    Giménez-Roldán S, Mateo D. Cinnarizine-induced parkinsonism. Susceptibility related to aging and essential tremor. Clin Neuropharmacol 1991; 14: 156–64PubMedGoogle Scholar
  30. 30.
    García-Ruiz P, García de Yébenes J, Jiménez-Jiménez FJ, et al. Parkinsonism associated to calcium channel blockers (CCB). A prospective follow-up study. Clin Neuropharmacol 1992; 15: 19–26PubMedGoogle Scholar
  31. 31.
    Laporte JR, Capellà D. Useless drugs are not placebos: lessons from flunarizine and cinnarizine [letter]. Lancet 1986; I: 853–4Google Scholar
  32. 32.
    Dick RS, Barold SS. Diltiazem-induced parkinsonism [letter]. Am J Med 1989; 87: 95–6PubMedGoogle Scholar
  33. 33.
    Malaterre HR, Lauribe P, Paganelli F, et al. Syndrome parkin-sonien, effet indesirable possible des inhibiteurs calciques. Arch Mal Coeur Vaiss 1992; 85: 1335–7PubMedGoogle Scholar
  34. 34.
    Graham DF, Stewart-Wynne EG. Diltiazem-induced acute parkinsonism. Aust N Z J Med 1994; 24: 70PubMedGoogle Scholar
  35. 35.
    García-Albea E, Jiménez-Jiménez FJ, Ayuso-Peralta L, et al. Parkinsonism unmasked by verapamil. Clin Neuropharmacol 1993; 16: 263–5PubMedGoogle Scholar
  36. 36.
    Padrell MD, Navarro M, Faura CC, et al. Verapamil-induced parkinsonism [letter]. Am J Med 1995; 99: 436PubMedGoogle Scholar
  37. 37.
    Sempere AP, Duarte J, Cabezas C, et al. Parkinsonism-induced by amlodipine. Mov Disord 1995; 10: 115–6PubMedGoogle Scholar
  38. 38.
    Nakashima K, Shimoda M, Kuno N, et al. Temporary symptom worsening caused by manidipine hydrochloride in two patients with parkinson’s disease. Mov Disord 1994; 9: 106–7PubMedGoogle Scholar
  39. 39.
    Grimes JD. Parkinsonism and tardive dyskinesia associated with long-term metoclopramide therapy. N Engl J Med 1981; 305: 1417PubMedGoogle Scholar
  40. 40.
    Grimes JD, Hassan MN, Preston DN. Adverse neurologic effects of metoclopramide. Can Med Assoc J 1982; 126: 23–5PubMedGoogle Scholar
  41. 41.
    Indo T, Ando K. Metoclopramide-induced parkinsonism. Clinical characteristics of ten cases. Arch Neurol 1982; 39: 494–6PubMedGoogle Scholar
  42. 42.
    Bateman DN, Rawlins MD, Simpson JM. Extrapyramidal reactions with metoclopramide. BMJ 1985; 291: 930–2PubMedGoogle Scholar
  43. 43.
    Yamamoto M, Ujike H, Ogawa N. Metoclopramide-induced parkinsonism. Clin Neuropharmacol 1987; 10: 287–9PubMedGoogle Scholar
  44. 44.
    Sethi KD, Patel B, Meador KJ. Metoclopramide-induced parkinsonism [letter]. South Med J 1989; 82: 1581–2PubMedGoogle Scholar
  45. 45.
    Miller LG, Jankovic J. Metoclopramide-induced movement disorders. Clinical findings with a review of the literature. Arch Intern Med 1989; 149: 2486–92PubMedGoogle Scholar
  46. 46.
    Bateman DN, Darling WM, Boys R, et al. Extrapyramidal reactions to metoclopramide and prochlorperazine. Q J Med 1989; 71: 307–11PubMedGoogle Scholar
  47. 47.
    Ganzini L, Casey DE, Hoffman WF, et al. The prevalence of metoclopramide-induced tardive dyskinesia and acute extra-pyramidal movement disorders. Arch Intern Med 1993; 153: 1469–75PubMedGoogle Scholar
  48. 48.
    Avorn J, Gurwitz JH, Bohn RL, et al. Increased incidence of levodopa therapy following metoclopramide use. JAMA 1995; 274: 1780–2PubMedGoogle Scholar
  49. 49.
    Montagna P, Gabellini AS, Monari L, et al. Parkinsonian syndrome after long-term treatment with clebopride. Mov Disord 1992; 7: 89–90PubMedGoogle Scholar
  50. 50.
    Jiménez-Jiménez FJ, Cabrera-Valdivia F, Ayuso-Peralta L, et al. Persistent parkinsonism and tardive dyskinesia-induced by clebopride. Mov Disord 1993; 8: 246–7PubMedGoogle Scholar
  51. 51.
    Sempere AP, Duarte J, Palomares JM, et al. Parkinsonism and tardive dyskinesia after chronic use of clebopride. Mov Disord 1994; 9: 114–5PubMedGoogle Scholar
  52. 52.
    Naito Y, Kuzuhara S. Parkinsonism-induced or worsened by cisapride. Nippon Ronen Igakkai Zasshi 1994; 31: 899–902PubMedGoogle Scholar
  53. 53.
    Micheli F, Gatto E, Fernández-Pardal M, et al. Domperidona y enfermedad de parkinson [letter]. Medicina (B Aires) 1988; 48:218Google Scholar
  54. 54.
    Milandre L, Ali-Cherif A, Khalil R. Syndrome parkinsonien au cours d’un traitement par le veralipride. Rev Med Interne 1991; 12: 157–8PubMedGoogle Scholar
  55. 55.
    Franchignoni FP, Tesio L. Sindrome parkinsoniana indotta da veralipride. Minerva Ginecol 1995; 47: 277–9PubMedGoogle Scholar
  56. 56.
    North RR. Drug-induced movement disorders. Postgrad Med 1971; 97: 882Google Scholar
  57. 57.
    Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and dyskinesias. Neurology 1988; 38: 391–4PubMedGoogle Scholar
  58. 58.
    Prusinski A, Kozubski W, Szymanska R, et al. Neurological side effects after using thietylperazine. Pol Tyg Lek 1983; 38: 1227–8PubMedGoogle Scholar
  59. 59.
    Bremnum J. Extrapyramidal side effects after long-term treatment with thiethylperazine. Ugeskr Laeger 1988; 150: 2827Google Scholar
  60. 60.
    Rosenblum AM, Montgomery EB. Exacerbation of parkinsonism by methyldopa [letter]. JAMA 1980; 244: 2727–8PubMedGoogle Scholar
  61. 61.
    Gillman MA, Sandyk R. Parkinsonism-induced by methyldopa. S Afr Med J 1984; 65: 194PubMedGoogle Scholar
  62. 62.
    Bouchard RH, Pourcher E, Vincent P. Fluoxetine and extra-pyramidal side effects [letter]. Am J Psychiatry 1989; 146: 1352–3Google Scholar
  63. 63.
    Tate JL. Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine. Am J Psychiatry 1989; 146: 399PubMedGoogle Scholar
  64. 64.
    Gernaat HBPE, Van de Woude J, Touw DJ. Fluoxetine and parkinsonism in patients taking carbamazepine [letter]. Am J Psychiatry 1991; 141: 118–9Google Scholar
  65. 65.
    Jansen Steur ENH. Increase of parkinson disability after fluoxetine medication. Neurology 1993; 43: 211–3Google Scholar
  66. 66.
    Daric C, Dollfus S, Mihout B, et al. Fluoxetine et symptomes extrapyramidaux. A propos de deux observations. Encéphale 1993; 19: 61–2PubMedGoogle Scholar
  67. 67.
    Gatto EM, Fernandez-Pardal M, Micheli F. Agravación del parkinsonismo por fluoxetina [letter]. Medicina (B Aires) 1994; 54: 182Google Scholar
  68. 68.
    Caley CF, Friedman JH. Does fluoxetine exacerbate parkinson’s disease? J Clin Psychiatry 1992; 53: 278–82PubMedGoogle Scholar
  69. 69.
    Montastruc JL, Fabre N, Blin O, et al. Does fluoxetine aggravate parkinson’s disease? A pilot prospective study. Mov Disord 1995; 10: 355–7PubMedGoogle Scholar
  70. 70.
    Jiménez-Jiménez FJ, Tejeiro J, Martínez-Junquera G, et al. Parkinsonism exacerbated by paroxetine. Neurology 1995; 45: 2406Google Scholar
  71. 71.
    Malek-Ahmadi P, Allen SA. Paroxetine-molindone interaction [letter]. J Clin Psychiatry 1995; 56: 82–3PubMedGoogle Scholar
  72. 72.
    Albanese A, Rossi P, Altavista MC. Can trazodone induce parkinsonism? Clin Neuropharmacol 1988; 11: 180–2PubMedGoogle Scholar
  73. 73.
    Teusink JP, Alexopoulos GS, Shamoian CA. Parkinsonian side effects-induced by a monoamine oxidase inhibitor [letter]. Am J Psychiatry 1984; 141: 118–9PubMedGoogle Scholar
  74. 74.
    Strouse TB, Salehmoghaddam S, Spar JE. Acute delirium and parkinsonism in a bupropion-treated liver transplant recipient [letter]. J Clin Psychiatry 1993; 54: 489–90PubMedGoogle Scholar
  75. 75.
    Lutz EG. Acute lithium-induced parkinsonism precipitated by liquid protein diet [letter]. J Med Soc N J 1978; 75: 165–6PubMedGoogle Scholar
  76. 76.
    Kane J, Rifkin A, Quitkin F, et al. Extrapyramidal side effects with lithium therapy. Am J Psychiatry 1978; 135: 851–3PubMedGoogle Scholar
  77. 77.
    Tyrer P, Alexander MS, Regan A, et al. An extrapyramidal syndrome after lithium therapy. Br J Psychiatry 1980; 136: 191–4PubMedGoogle Scholar
  78. 78.
    Gajkowski K, Werkowicz-Pelczyk D, Masiak I, et al. Neurologic symptoms in lithium poisoning. Neurol Neurochir Pol 1987; 21: 412–4PubMedGoogle Scholar
  79. 79.
    Holroyd S, Smith D. Disabling parkinsonism due to lithium: a case report [letter]. J Geriatr Psychiatry Neurol 1995; 8: 118–9PubMedGoogle Scholar
  80. 80.
    Suranyi-Cadotte BE, Nestoros JN, Nair NPV, et al. Parkinsonism-induced by high doses of diazepam. Biol Psychiatry 1985; 20: 451–60Google Scholar
  81. 81.
    van der Zwan Jr A. Transient parkinson syndrome and tremor caused by the use of sodium valproate. Ned Tijdschr Genee-skd 1989; 133: 1230–2Google Scholar
  82. 82.
    Alvarez-Gomez MJ, Vaamonde J, Narbona J, et al. Parkinsonian syndrome in childhood after sodium valproate administration. Clin Neuropharmacol 1993; 16: 451–5PubMedGoogle Scholar
  83. 83.
    Sasso E, Delsoldato S, Negrotti A, et al. Reversible valproate-induced extrapyramidal disorders. Epilepsia 1994; 35: 391–3PubMedGoogle Scholar
  84. 84.
    Froomes PR, Stewart MR. A reversible parkinsonian syndrome and hepatotoxocity following addition of carbamazepine to sodium valproate. Aust N Z J Med 1994; 24: 413–4PubMedGoogle Scholar
  85. 85.
    Goñi M, Jiménez M, Scijoo M. Parkinsonism-induced by phenytoin. Clin Neuropharmacol 1985; 8: 383–4PubMedGoogle Scholar
  86. 86.
    Fox JH, Bennett DA, Goetz CG, et al. Induction of parkinsonism by intraventricular bethanechol in a patient with Alzheimer’s disease. Neurology 1989; 9: 1265Google Scholar
  87. 87.
    Iwasaki Y, Wakata N, Kinoshita M. Parkinsonism-induced by pyridostigmine. Acta Neurol Scand 1988; 78: 236PubMedGoogle Scholar
  88. 88.
    LeMarie JF, Autret A, Biziere K, et al. Amiodarone neuropathy. Further arguments for human drug-induced neurolipidosis. Eur Neurol 1987; 147: 881–4Google Scholar
  89. 89.
    Palakurthy PR, Iyer V, Meckler RJ. Unusual neurotoxicity associated with amiodarone therapy. Arch Intern Med 1987; 147: 881–4PubMedGoogle Scholar
  90. 90.
    Werner EG, Olanow CW. Parkinsonism and amiodarone therapy. Ann Neurol 1989; 25: 630–2PubMedGoogle Scholar
  91. 91.
    Dotti MT, Federico A. Amiodarone-induced parkinsonism: a case report and pathogenetic discussion. Mov Disord 1995; 10: 233–4PubMedGoogle Scholar
  92. 92.
    Gjerris F. Transitory procaine-induced parkinsonism. J Neurol Neurosurg Psychiatry 1971; 34: 20–2PubMedGoogle Scholar
  93. 93.
    Lieberman AN, Goldstein M. Reversible parkinsonism related to meperidine [letter]. N Engl J Med 1985; 8: 509Google Scholar
  94. 94.
    Olive JM, Masana L, Gonzalez J. Meperidine and reversible parkinsonism. Mov Disord 1994; 9: 115–6PubMedGoogle Scholar
  95. 95.
    Fisher JF, Dewald J. Parkinsonism associated with intra-ventricular amphotericine B. J Antimicrob Ther 1983; 12: 97–9Google Scholar
  96. 96.
    Balmaceda CM, Walker RW, Castro-Malaspina H, et al. Reversal of amphotericin-B-related encephalopathy. Neurology 1994; 44: 1183–4PubMedGoogle Scholar
  97. 97.
    Mintz U, Liberman UA, Vries A. Parkinsonism syndrome due to cephaloridine [letter]. JAMA 1971; 216: 1200PubMedGoogle Scholar
  98. 98.
    Shaunak S, Brown P, Morgan-Hughes JA. Exacerbation of id-iopathic Parkinson’s disease by naproxen [letter]. BMJ 1995; 311:422PubMedGoogle Scholar
  99. 99.
    Fernandez W, Lees AJ. Temporary deterioration in parkinsonian signs after modest alcohol intake. Mov Disord 1992; 7: 284–5PubMedGoogle Scholar
  100. 100.
    Yasui M, Kihira T, Ota K, et al. A case of parkinsonism-induced by an oral contraceptive. No To Shinkei 1992; 44: 163–6PubMedGoogle Scholar
  101. 101.
    Fujisawa Y, Tsuji T, Sasaki K. Parkinsonism-induced by in-deloxazine hydrochloride. Clin Ther 1989; 11: 807–11PubMedGoogle Scholar
  102. 102.
    Ogawa N. Parkinsonism-induced by indeloxazine hydrochloride in the elderly. Clin Ther 1989; 11: 802–6PubMedGoogle Scholar
  103. 103.
    Shimoda K, Hikasa C, Nishikawa S, et al. A case report of captopril-induced parkinsonism. Rinsho Shinkeigaku 1987; 27: 366–8PubMedGoogle Scholar
  104. 104.
    Luque FA, Scihorst JB, Petruska P. Parkinsonism-induced by high-dose cytosine arabinoside. Mov Disord 1987; 2: 219–22PubMedGoogle Scholar
  105. 105.
    Weiden PJ, Mann JJ, Haas G, et al. Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study. Am J Psychiatry 1987; 144: 1148–53PubMedGoogle Scholar
  106. 106.
    Hansen TE, Brown WL, Weigel RM, et al. Underrecognition of tardive dyskinesia and drug-induced parkinsonism by psychiatric residents. Gen Hosp Psychiatry 1992; 14: 340–4PubMedGoogle Scholar
  107. 107.
    Farde L, Nordstrom AL, Wiesel AL, et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. J Clin Psychiatry 1992; 9: 538–44Google Scholar
  108. 108.
    Grohmann R, Koch R, Schmidt LG. Extrapyramidal symptoms in neuroleptic recipients. Agents Actions 1990; 29 Suppl.: 71–82Google Scholar
  109. 109.
    Weiner WJ, Lang AE. Drug-induced movement disorders (not including tardive dyskinesia). In: Weiner WJ, Lang AE, editors. Movement disorders. A comprehensive survey. Mount Kisco, New York: Futura Publishing Co., 1989: 599–644Google Scholar
  110. 110.
    Chouinard G. Early phase II clinical trial of remoxipride in treatment of schizophrenia with measurements of prolactin and neuroleptic activity. J Clin Psychopharmacol 1987; 7: 159–64PubMedGoogle Scholar
  111. 111.
    Laux G, Klieser E, Schroder HG, et al. A double-blind multi-centre study comparing remoxipride, two and three times daily, with haloperidol in schizophrenia. Acta Psychiatr Scand 1990; 358 Suppl.: 125–9Google Scholar
  112. 112.
    Lindstrom LH, Wieseigren IM, Struwe G, et al. A double- blind comparative multicentre study of remoxipride and haloperidol in schizophrenia. Acta Psychiatr Scand 1990; 358 Suppl.: 130–5Google Scholar
  113. 113.
    Kane JM, Safferman AZ, Pollack S, et al. Clozapine, negative symptoms, and extrapyramidal side effects. J Clin Psychiatry 1994: 55 Suppl. B: 74–7PubMedGoogle Scholar
  114. 114.
    Gerlach J, Peacock L. Motor and mental side effects of clozapine. J Clin Psychiatry 1994: 55 Suppl. B: 107–9PubMedGoogle Scholar
  115. 115.
    Bezchlibnyk-Butler KZ, Remington GJ. Antiparkinsonian drugs in the treatment of neuroleptic-induced extrapyramidal symptoms. Can J Psychiatry 1994; 39: 74–84PubMedGoogle Scholar
  116. 116.
    Kurz M, Hummer M, Oberbauer H, et al. Extrapyramidal side effects of clozapine and haloperidol. Psychopharmacology (Berl) 1995; 118: 52–6Google Scholar
  117. 117.
    Owens DGC. Adverse effects of antipsychotic agents. Do newer agents offer advantages? Drugs 1996; 51: 895–930PubMedGoogle Scholar
  118. 118.
    Sandyk R, Kay SR. Drug-induced parkinsonism: relationship to age at onset of schizophrenia. Funct Neurol 1991; 6: 151–7PubMedGoogle Scholar
  119. 119.
    Hoffman WF, Labs SM, Casey DE. Neuroleptic-induced parkinsonism in older schizophrenics. Biol Psychiatry 1987; 22: 427–39PubMedGoogle Scholar
  120. 120.
    Prosser ES, Csernansky JG, Kaplan J, et al. Depression, parkinsonian symptoms, and negative symptoms in schizophrenics treated with neuroleptics. J Nerv Ment Dis 1987; 175: 100–5PubMedGoogle Scholar
  121. 121.
    Nelli AC, Yarden PE, Guazzelli M, et al. Parkinsonism following neuroleptic withdrawal. Arch Gen Psychiatry 1989; 46: 383–4PubMedGoogle Scholar
  122. 122.
    Melamed E, Achiron A, Shapira A, et al. Persistent and progressive parkinsonism after discontinuation of chronic neuroleptic therapy: an additional tardive syndrome? Clin Neuro-pharmacol 1991; 14: 273–8Google Scholar
  123. 123.
    Burkhardt C, Kelly JP, Lim YH, et al. Neuroleptic medications inhibit complex I of the electron transport chain. Ann Neurol 1993; 33: 512–7PubMedGoogle Scholar
  124. 124.
    Schapira AHV, Cooper JM, Dexter D, et al. Mitochondrial complex I deficiency in Parkinson’s disease [letter]. Lancet 1989; I: 1269Google Scholar
  125. 125.
    Mizuno Y, Ohta S, Tanaka S, et al. Deficiencies in complex I subunits of the respiratory chain in Parkinson’s disease. Biochem Biophys Res Commun 1989; 163: 1450–5PubMedGoogle Scholar
  126. 126.
    Negrotti A, Calzetti S, Sasso E. Calcium-entry Mockers—induced parkinsonism: possible role of inherited susceptibility. Neurotoxicology 1992; 13: 261–4PubMedGoogle Scholar
  127. 127.
    García-Ruiz PJ, Mena MA, Penafiel N, et al. Cinnarizine-in-duced parkinsonism in primates. Clin Neuropharmacol 1992; 15: 152–4PubMedGoogle Scholar
  128. 128.
    Pileblad E, Carlsson A. The Ca2+ antagonist nimodipine decreases and the Ca2+ agonist BAY K 8644 increases catechol-amine synthesis in mouse brain. Neuropharmacology 1987; 26: 101–5PubMedGoogle Scholar
  129. 129.
    Yarom M, Zurgil N, Zisapel N. Calcium permeability changes and neurotransmitter release in cultured brain neurons. II. Temporal analysis of neurotransmitter release. J Biol Chem 1985; 260: 16294–302PubMedGoogle Scholar
  130. 130.
    Barochovsky O, Bradford HE Development of transmitter- releasing capacity in neuron-enriched tissue cultures. J Neurochem 1987; 48: 787–97PubMedGoogle Scholar
  131. 131.
    Pardo B, Casarejos MJ, Tabernero C, et al. Farmacología de los antagonistas del calcio sobre el sistema dopaminérgico [abstract]. Neurología (Spain) 1989; 4: 160Google Scholar
  132. 132.
    De Vries DJ, Beart PM. Competitive inhibition of [3H]spiperone binding to D-2 dopamine receptors in striatal homogenates by organic calcium-channel antagonists and polivaient cations. Eur J Pharmacol 1985; 106: 133–9Google Scholar
  133. 133.
    De Yébenes MJG, Casarejos MJ, Mena MA, et al. Effects of calcium antagonists on dopamine-rich human neuroblastoma cells, NB69 [abstract]. Mov Disord 1992; 7 Suppl. 1: 61Google Scholar
  134. 134.
    Kariya S, Isozaki S, Masubuchi Y, et al. Possible pharmacokinetic and pharmacodynamic factors affecting parkinsonism inducement by cinnarizine and flunarizine. Biochem Pharmacol 1995; 50: 1645–50PubMedGoogle Scholar
  135. 135.
    Veitch K, Hue L. Flunarizine and cinnarizine inhibit mitochondrial complexes I and II: possible implication for parkinson-ism. Mol Pharmacol 1994; 45: 158–63PubMedGoogle Scholar
  136. 136.
    Montastruc JL, Llau ME, Rascol O, et al. Drug-induced parkinsonism: a review. Fundam Clin Pharmacol 1994; 8: 293–306PubMedGoogle Scholar
  137. 137.
    Richardson MA, Craig TJ. The coexistence of parkinsonism-like symptoms and tardive dyskinesia. Am J Psychiatry 1982; 19: 341–3Google Scholar
  138. 138.
    Jankovic J, Casabona J. Coexistent tardive dyskinesia and parkinsonism. Clin Neuropharmacol 1987; 10: 511–21PubMedGoogle Scholar
  139. 139.
    Stephen PJ, Williamson J. Drug-induced parkinsonism in the elderly. Lancet 1984; II: 1082–3Google Scholar
  140. 140.
    Remington G, Bezchlibnyk-Butler K. Management of acute antipsychotic-induced extrapyramidal syndromes. CNS Drugs 1996; 5 Suppl. 1:21–35Google Scholar
  141. 141.
    Barnes TRE, McPhillips MA. Antipsychotic-induced extra-pyramidal symptoms. Role of anticholinergic drugs in treatment. CNS Drugs 1996; 6: 315–30Google Scholar
  142. 142.
    Hardie RJ, Lees AJ. Neuroleptic-induced Parkinson’s syndrome: clinical features and results of treatment with levo-dopa. J Neurol Neurosurg Psychiatry 1988; 51: 850–4PubMedGoogle Scholar
  143. 143.
    Stacy M, Jankovic J. Tardive tremor. Mov Disord 1992; 7: 53–7PubMedGoogle Scholar
  144. 144.
    Arblaster LA, Lakie M, Mutch WJ, et al. A study of the early signs of drug-induced parkinsonism. J Neurol Neurosurg Psychiatry 1993; 56: 301–3PubMedGoogle Scholar
  145. 145.
    Gabellini AS, Martinelli P, Coccagna G. Drug-induced tremor of the tongue. Ital J Neurol Sci 1989; 10: 89–91PubMedGoogle Scholar
  146. 146.
    Friedman JH. ‘Rubral’ tremor-induced by a neuroleptic drug. Mov Disord 1992; 7: 281–2PubMedGoogle Scholar
  147. 147.
    Tan U, Gepdiremen A, Banoglu N, et al. Intermittent tremor-bursts-induced by chlorpromazine and pentobarbitone in guinea pigs: a new tremor model. Int J Neurosci 1991; 61: 221–8PubMedGoogle Scholar
  148. 148.
    Gelenberg AJ, Jefferson JW. Lithium tremor. J Clin Psychiatry 1995; 56: 283–7PubMedGoogle Scholar
  149. 149.
    Schou M, Baastrup PC, Grof P, et al. Pharmacological and clinical problems of lithium prophylaxis. Br J Psychiatry 1970; 116: 615–9PubMedGoogle Scholar
  150. 150.
    Karas BJ, Wilder BJ, Hammond EJ, et al. Valproate tremors. Neurology 1982; 2: 428–32Google Scholar
  151. 151.
    Lejoyeux M, Rouillon F, Ades J, et al. Neural symptoms-induced by tricyclic antidepressants: phenomenology and pathophysiology. Acta Psychiatr Scand 1992; 85: 249–56PubMedGoogle Scholar
  152. 152.
    Lejoyeux M, Rouillon F, Ades J. Prospective evaluation of the serotonin syndrome in depressed inpatients treated with clomipramine. Acta Psychiatr Scand 1993; 88: 369–71PubMedGoogle Scholar
  153. 153.
    Larsen K, Schmekel B. Tremor in healthy volunteers after bambuterol and terbutaline CR tablets. Eur J Clin Pharmacol 1993; 45: 303–5PubMedGoogle Scholar
  154. 154.
    Weiner WJ, Lang AE. Tremor. In: Weiner WJ, Lang AE, editors. Movement disorders. A comprehensive survey. Mount Kisco, NY: Futura Publishing Co., 1989: 221–56Google Scholar
  155. 155.
    Logan WJ, Freeman JM. Pseudodegenerative disease due to diphenylhydantoin intoxication. Arch Neurol 1969; 21: 631–7PubMedGoogle Scholar
  156. 156.
    Taira T. Zonisamide-induced tremor: report of two cases. No To Shinkei 1992; 44: 61–3PubMedGoogle Scholar
  157. 157.
    Reutens DC, Duncan JS, Patsalos PN. Disabling tremor after lamotrigine with sodium valproate [letter]. Lancet 1993; 42: 185–6Google Scholar
  158. 158.
    Kaminski CA, Robbins MS, Weibley RE. Sertraline intoxication in a child. Ann Emerg Med 1994; 23: 1371–4PubMedGoogle Scholar
  159. 159.
    Apseloff G, Wilner KD, von Deutsch DA, et al. Sertraline does not alter steady-state concentrations or renal clearance of lithium in healthy volunteers. J Clin Pharmacol 1992; 32: 643–6PubMedGoogle Scholar
  160. 160.
    Debattista C, Schatzberg AF. Physical symptoms associated with paroxetine withdrawal [letter]. Am J Psychiatry 1995; 152: 1234–5Google Scholar
  161. 161.
    Soto J, Sacristán JA, Alsar MJ, et al. Terfenadine-induced tremor. Ann Neurol 1993; 33: 226PubMedGoogle Scholar
  162. 162.
    Laguna-del-Estal P, Calabrese S, Zabala JA, et al. Toxicidad neurölogica por antimoniales pentavalentes durante el tratamiento de la leishmaniasis visceral. Med Clín (Barc) 1994; 102: 276–7Google Scholar
  163. 163.
    Cardoso FE, Jankovic J. Cocaine-related movement disorders. Mov Disord 1993; 8: 175–8PubMedGoogle Scholar
  164. 164.
    Findley LJ. Tremors: differential diagnosis and pharmacology. In: Jankovic J, Tolosa E, editors. Parkinson’s disease and movement disorders, 2nd ed. Baltimore: Williams & Wilkins, 1993:293–313Google Scholar
  165. 165.
    Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967; 276: 567–72Google Scholar
  166. 166.
    Papavasiliou PS, Cotzias GC, Duby SE, et al. Levodopa in parkinsonism: potentiation of central effects with a peripheral inhibitor. N Engl J Med 1972; 285: 8–14Google Scholar
  167. 167.
    Barbeau A. Treatment with levodopa and R04-4602: review and present status. Adv Neurol 1973; 2: 173–98Google Scholar
  168. 168.
    Martín WE, Tolosa ES, Loewenson RL, et al. The effect of combining carbidopa with levodopa for Parkinson’s disease. Geriatrics 1975; 30: 39–44PubMedGoogle Scholar
  169. 169.
    Sage JI, Mark MH, McHale DM, et al. Benefits of monitoring plasma levodopa in Parkinson’s disease patients with drug-induced chorea. Ann Neurol 1991; 29: 623–8PubMedGoogle Scholar
  170. 170.
    Marconi R, Lefebvre-Caparros D, Bonnet AM, et al. Levodopa-induced dyskinesias in Parkinson’s disease: phenomenology and pathophysiology. Mov Disord 1994; 9: 2–12PubMedGoogle Scholar
  171. 171.
    Zimmerman Jr TR, Sage JI, Lang AE, et al. Severe evening dyskinesias in advanced Parkinson’s disease: clinical description, relation to plasma levodopa, and treatment. Mov Disord 1994; 9: 173–7PubMedGoogle Scholar
  172. 172.
    Calne DB, Techeyne PF, Clavería LE, et al. Bromocriptine in Parkinson’s disease. BMJ 1974; 4: 442–4PubMedGoogle Scholar
  173. 173.
    Cotzias GC, Papavasiliou PS, Tolosa E, et al. Treatment of Parkinson’s disease with aporphines. Possible role of growth hormones. N Engl J Med 1976; 294: 567–72PubMedGoogle Scholar
  174. 174.
    Lieberman A, Goldstein M, Leibowitz M, et al. Treatment of advanced Parkinson’s disease with pergolide. Neurology 1981; 31: 675–82PubMedGoogle Scholar
  175. 175.
    McDonald RJ, Horowski L. Lisuride in the treatment of parkinsonism. Eur Neurol 1983; 22: 240–55PubMedGoogle Scholar
  176. 176.
    Le Witt P. Clinical and pharmacological aspects of the anti-parkinsonian ergoline lisuride. In: Fahn S, Marsden CD, Jenner P, et al., editors. Recent developments in Parkinson’s disease. New York: Raven Press, 1986: 347–54Google Scholar
  177. 177.
    Klawans HL, Weiner WJ. The effect of d-amphetamine on choreiform movement disorders. Neurology 1974; 24: 312–8PubMedGoogle Scholar
  178. 178.
    Lundh H, Tunving K. An extrapyramidal choreiform syndrome caused by amphetamine addiction. J Neurol Neurosurg Psychiatry 1981; 44: 728–30PubMedGoogle Scholar
  179. 179.
    Rhee KJ, Albertson TE, Douglas JC. Choreoathetoid disorder associated with amphetamine-like drugs. Am J Emerg Med 1988; 6: 131–3PubMedGoogle Scholar
  180. 180.
    Sperling LS, Horowitz JL. Methamphetamine-induced choreoathetosis and rhabdomyolysis. Ann Intern Med 1994; 34: 388–90Google Scholar
  181. 181.
    Nausieda PA, Coller WC, Weiner WJ, et al. Pemoline-induced chorea. Neurology 1981; 31: 356–60PubMedGoogle Scholar
  182. 182.
    Weiner WJ, Nausieda PA, Klawans HL. Methylphenidate-in-duced chorea: case report and pharmacologic implications. Neurology 1979; 29: 1041–4Google Scholar
  183. 183.
    Habal R, Sauter D, Olowe O, et al. Cocaine and chorea. Am J Emerg Med 1991; 9: 618–20PubMedGoogle Scholar
  184. 184.
    Stuart AM, Worley LM, Spillane J. Choreiform movements observed in an 8-year-old child following use of an oral theo-phylline preparation. Clin Pediatr Phila 1992; 1: 692–4Google Scholar
  185. 185.
    Birket-Smith E. Abnormal involuntary movements-induced by anticholinergic therapy. Acta Neurol Scand 1974; 50: 801–11PubMedGoogle Scholar
  186. 186.
    Warne RW, Gubbay SS. Choreiform movements-induced by anticholinergic therapy [letter]. Med J Aust 1979; 1: 465PubMedGoogle Scholar
  187. 187.
    Matsumoto K, Nogaki H, Morimatsu M. A case of choreo-athetoid movements-induced by anticholinergic drugs, tryhexy-phenidyl HC1 and dosulepin HC1. Nippon Ronen Igakkai Zasshi 1992; 29: 686–9PubMedGoogle Scholar
  188. 188.
    Nomoto M, Thompson PD, Sheehy MP, et al. Anticholinergic-induced chorea in the treatment of focal dystonia. Mov Disord 1987; 2: 53–6PubMedGoogle Scholar
  189. 189.
    Thach BT, Chase TN, Bosma J. Oral facial dyskinesia associated with prolonged use of antihistaminic decongestants [letter]. N Engl J Med 1975; 293: 486–7PubMedGoogle Scholar
  190. 190.
    Lehmann AB. Reversible chorea due to ranitidine and cimetidine [letter]. Lancet 1988; II: 158Google Scholar
  191. 191.
    Nausieda PA, Koller WC, Weiner WJ, et al. Chorea-induced by oral contraceptives. Neurology 1979; 29: 1605–9PubMedGoogle Scholar
  192. 192.
    Bedard P, Langelier P, Danbova J, et al. Estrogens, progesterone and the extrapyramidal system. Adv Neurol 1979; 24: 411–22Google Scholar
  193. 193.
    Galimberti D. Chorea-induced by the use of oral contraceptives. Report of a case and review of the literature. Ital J Neurol Sci 1987; 8: 383–6PubMedGoogle Scholar
  194. 194.
    Leys D, Destee A, Petit H, et al. Chorea associated with oral contraception. J Neurol 1987; 235: 46–8PubMedGoogle Scholar
  195. 195.
    Driesen JJ, Wolters EC. Oral contraceptive-induced paraballism. Clin Neurol Neurosurg 1987; 89: 49–51PubMedGoogle Scholar
  196. 196.
    Mathur AK, Gatter RA. Chorea as the initial presentation of oral contraceptive-induced systemic lupus erythematosus. J Rheumatol 1988; 15: 1042–3PubMedGoogle Scholar
  197. 197.
    Liedholm LJ, Barajas F. Oral contraceptives causing chorea in a young woman [letter]. Lakartidningen 1988; 85: 448PubMedGoogle Scholar
  198. 198.
    Cocito D, Gallo G. Hemichorea-induced by oral contraceptive use. Ital J Neurol Sci 1989; 10: 217–8PubMedGoogle Scholar
  199. 199.
    Profumo R, Toce S, Kotagal S. Neonatal choreoathetosis following prenatal exposure to oral contraceptives. Pediatrics 1990; 86: 648–9PubMedGoogle Scholar
  200. 200.
    Caviness JN, Muenter MD. An unusual cause of recurrent chorea. Mov Disord 1991; 6: 355–7PubMedGoogle Scholar
  201. 201.
    Steiger MJ, Quinn NP. Hormone replacement therapy-induced chorea [letter]. BMJ 1991; 302: 762PubMedGoogle Scholar
  202. 202.
    Chadwick D, Reynolds EG, Marsden CD. Anticonvulsant-in-duced dyskinesias: a comparison with dyskinesias-induced by neuroleptics. J Neurol Neurosurg Psychiatry 1976; 9: 1210–8Google Scholar
  203. 203.
    Filloux F, Thompson JA. Transient chorea-induced by phenytoin. J Pediatr 1987; 110: 639–41PubMedGoogle Scholar
  204. 204.
    Szczechowski L, Rosciszewska D. Choreoathetotic movements in a patient with epilepsy after treatment with diphenylhydan-toin. Neurol Neurochir Pol 1987; 21: 255–7PubMedGoogle Scholar
  205. 205.
    Martinón-Sánchez F, Viso-Lorenzo JA. Una observation pediátrica de coreoatetosis por difenilhidantoína. An Esp Pediatr 1990; 32: 554–5PubMedGoogle Scholar
  206. 206.
    Martínez-Orgado J, García-Aparicio J, Cabanillas-Vilaplana L, et al. Coreoatetosis inducida por difenilhidantoína en un lactante con síndrome CHARGE. An Esp Pediatr 1990; 33: 384–6PubMedGoogle Scholar
  207. 207.
    Haider Y, Abbott RJ. Phenytoin-induced choreoathetosis [letter]. Postgrad Med J 1990; 66: 1089PubMedGoogle Scholar
  208. 208.
    Harrison MD, Lyons GR, Landow ER. Phenytoin and dyskinesias: a report of two cases and review of the literature. Mov Disord 1993: 8: 19–27PubMedGoogle Scholar
  209. 209.
    Shulman LM, Singer C, Weiner WJ. Phenytoin-induced focal chorea. Mov Disord 1996; 11: 111–4PubMedGoogle Scholar
  210. 210.
    Weaver DF, Camfield P, Fraser A. Massive carbamazepine overdose: clinical and pharmacologie observations in five episodes. Neurology 1988; 38: 755–9PubMedGoogle Scholar
  211. 211.
    Mosquet B, Starace J, Madelaine S, et al. Syndrome choreo-athetosique sous carbamazepine et viloxazine. Consequence d’une interaction médicamenteuse? Therapie 1994; 49: 513–4Google Scholar
  212. 212.
    Kirschberg GJ. Dyskinesia: an unusual reaction to ethosuximide. Arch Neurol 1975; 32: 137–8PubMedGoogle Scholar
  213. 213.
    Lancman ME, Asconape JJ, Penry JK. Choreiform movements associated with the use of valproate. Arch Neurol 1994; 51: 702–4PubMedGoogle Scholar
  214. 214.
    Kerrick JM, Kelley BJ, Maister BH, et al. Involuntary movement disorders associated with felbamate. Neurology 1995; 45: 185–7PubMedGoogle Scholar
  215. 215.
    Buetefisch CM, Gutiérrez A, Gutmann L. Choreoathetotic movements: a possible side effect of gabapentin. Neurology 1996; 46: 851–2PubMedGoogle Scholar
  216. 216.
    Patrick SJ, Snelling LK, Ment LR. Infantile chorea following abrupt withdrawal of diazepam and pentobarbital therapy. J Toxicol Clin Toxicol 1993; 31: 127–32PubMedGoogle Scholar
  217. 217.
    Fann WE, Sullivan JL, Richman BW. Dyskinesias associated with tricyclic antidepressants. Br J Psychiatry 1976; 128: 490–3PubMedGoogle Scholar
  218. 218.
    Sandyk R. Nomifensine-induced orofacial dyskinesia and Sydenham’s chorea. Int J Neurosci 1987; 35: 91–2PubMedGoogle Scholar
  219. 219.
    Patterson JP. Amoxapine-induced chorea [letter]. South Med J 1983; 76: 1077PubMedGoogle Scholar
  220. 220.
    Marchioni E, Perucca E, Soragna D, et al. Choreiform syndrome associated with fluoxetine treatment in a patient with deficient CYP2D6 activity. Neurology 1996; 46: 853PubMedGoogle Scholar
  221. 221.
    Zorumski CP, Bakris GL. Choreoathetosis associated with lithium: case report and literature review. Am J Psychiatry 1983; 140: 1621–2PubMedGoogle Scholar
  222. 222.
    Walevski A, Radwan M. Choreoathetosis as toxic effect of lithium treatment. Eur Neurol 1986; 25: 412–5PubMedGoogle Scholar
  223. 223.
    Matsis PP, Fisher RA, Tasman-Jones C. Acute lithium toxicity: chorea, hypercalcemia and hyperamylasemia. Aust N Z J Med 1989; 19: 718–20PubMedGoogle Scholar
  224. 224.
    Reed SM, Wise MG, Timmerman I. Choreoathetosis: a sign of lithium toxicity. J Neuropsychiatry Clin Neurosci 1989; 1: 57–60PubMedGoogle Scholar
  225. 225.
    Helmuth D, Ljaljevic Z, Ramirez L, et al. Choreoathetosis-in-duced by verapamil and lithium treatment. J Clin Psy-chopharmacol 1989; 9: 454–5Google Scholar
  226. 226.
    Tsuda N, Negoro K, Morimatsu M. A case of multiple cerebral infarctions associated with hemichorea-induced by amantadine hydrochloride. Rinsho Shinkeigaku 1994; 34: 388–90PubMedGoogle Scholar
  227. 227.
    Tilzey A, Heptonstall J, Hamblin T. Toxic confusional state and choreiform movements after treatment with anabolic steroids. BMJ 1981; 283: 343–50Google Scholar
  228. 228.
    Wasserman S, Yahr MD. Choreic movements-induced by the use of methadone. Arch Neurol 1980; 37: 727–8PubMedGoogle Scholar
  229. 229.
    Crystal HA. Baclofen therapy may be associated with chorea in Alzheimer’s disease. Ann Neurol 1990; 28: 839PubMedGoogle Scholar
  230. 230.
    Kaplan SR, Murkofsky C. Oral-buccal dyskinesia symptoms associated with low-dose benzodiazepine treatment [letter]. Am J Psychiatry 1978; 135: 1558–9PubMedGoogle Scholar
  231. 231.
    Neil EM, Waters AK. Generalized choreiform movements as a complication of methyldopa therapy in chronic renal failure. Postgrad Med J 1981; 57: 732–3PubMedGoogle Scholar
  232. 232.
    Kaminsky P, Cosmidis S, Debouverie M, et al. Syndrome choreiforme provoque par l’alpha-methyldopa [letter]. Therapie 1988; 43: 239PubMedGoogle Scholar
  233. 233.
    Wedzicha JA, Gibb WR, Lees AJ, et al. Chorea in digoxin toxicity [letter]. J Neurol Neurosurg Psychiatry 1984; 47: 419PubMedGoogle Scholar
  234. 234.
    Mulder LJ, Van der Mast RC, Meerwaldt JD. Generalised chorea due to digoxin toxicity [letter]. BMJ 1988; 296: 1262PubMedGoogle Scholar
  235. 235.
    Neary O, Thurston H, Pohl JE. Development of extrapyramidal symptoms in hypertensive patients treated with diazoxide [letter]. BMJ 1973; 3: 474–5PubMedGoogle Scholar
  236. 236.
    Vernay D, Dubost JJ, Thevenet JP, et al. ‘Choree fibrillaire de Morvan’ followed by Guillain-Barre syndrome in a patient receiving gold therapy [letter]. Arthritis Rheum 1986; 29: 1413–4PubMedGoogle Scholar
  237. 237.
    Aumaitre O, Vernay D, Marcheix JC, et al. Choree fibrillaire de Morvan secondaire à un traitement par sels d’or. Presse Med 1988; 17: 2140PubMedGoogle Scholar
  238. 238.
    Petiot P, Charles N, Vial C, et al. Complications neurologiques des sels d’or: discussion nosologique a propos d’un cas. Rev Neurol (Paris) 1993; 149: 562–5Google Scholar
  239. 239.
    Sarnie MR, Ashton AK. Choreoathetosis-induced by cyproheptadine. Mov Disord 1989; 4: 81–4Google Scholar
  240. 240.
    Combarros O, Fábrega E, Polo JM, et al. Cyclosporine-induced chorea after liver transplantation for Wilson’s disease. Ann Neurol 1993; 33: 108–9PubMedGoogle Scholar
  241. 241.
    Quinn AG, Ellis WR, Burn D, et al. Chorea precipitated by sulphasalazine [letter]. BMJ 1991; 302: 1025PubMedGoogle Scholar
  242. 242.
    Burguet A, Menget A, Fromentin C, et al. Effets neurologiques de l’aciclovir apres greffe de moelle allogenique. Arch Fr Pediatr 1988; 45: 343–5PubMedGoogle Scholar
  243. 243.
    McHugh P. Acute choreoathetoid reaction to propofol [letter]. Anaesthesia 1991; 46: 425PubMedGoogle Scholar
  244. 244.
    Borgeat A, Wilder-Smith O. Acute choreoathetoid reaction to propofol [letter]. Anaesthesia 1991; 46: 797PubMedGoogle Scholar
  245. 245.
    Tanner CM, Melamed E, Lees AJ. Managing motor fluctuations, dyskinesias, and other adverse effects in Parkinson’s disease. Neurology 1994; 44 Suppl. 1: S12–S16PubMedGoogle Scholar
  246. 246.
    Shale H, Tanner C. Pharmacological options for the management of dyskinesias. Drugs 1996; 52: 849–60PubMedGoogle Scholar
  247. 247.
    Koller WC, Silver DE, Lieberman A. An algorithm for the management of Parkinson’s disease. Neurology 1994; 44 Suppl. 10: S1–S52PubMedGoogle Scholar
  248. 248.
    Bennet JP, Landow ER, Schuh LA. Suppression of dyskinesias in advanced Parkinson’s disease. II. Increasing daily clozap-ine doses suppress dyskinesias and improve parkinsonism symptoms. Neurology 1999; 43: 1551–5Google Scholar
  249. 249.
    Kleerdorfer B, Lees AJ, Stern GM. Buspirone in the treatment of levodopa-induced dyskinesias [letter]. J Neurol Neurosurg Psychiatry 1991; 54: 376–7Google Scholar
  250. 250.
    Bonifati V, Fabrizio E, Cipriani R, et al. Buspirone in levodopa-induced dyskinesias. Clin Neuropharmacol 1994; 17: 99–102Google Scholar
  251. 251.
    Durif F, Vidailhet M, Bonnet AM, et al. Levodopa-induced dyskinesias are improved by fluoxetine. Neurology 1956; 45: 1855–8Google Scholar
  252. 252.
    Tarsy D, Leopold N, Sax D. Physostigmine in choreiform movement disorders. Neurology 1974; 24: 28–34PubMedGoogle Scholar
  253. 253.
    Klawans HL, Topel JL, Bergen D. Deanol in the treatment of levodopa-induced dyskinesias. Neurology 1975; 25: 290–3PubMedGoogle Scholar
  254. 254.
    Price PA, Parkes JD, Marsden CD. Sodium valproate in the treatment of levodopa-induced dyskinesias. J Neurol Neurosurg Psychiatry 1978; 41: 702–6PubMedGoogle Scholar
  255. 255.
    Ziegler M, Fournier V, Bathien N, et al. Therapeutic response to progabide in neuroleptic and levodopa-induced dyskinesias. Clin Neuropharmacol 1987; 10: 238–46PubMedGoogle Scholar
  256. 256.
    Turjanski N, Lees AJ. Gamma vinyl GAB A in the treatment of levodopa-induced dyskinesias [letter]. J Neurol Neurosurg Psychiatry 1992; 55: 413PubMedGoogle Scholar
  257. 257.
    Gershanik OS, Luquin MR, Scipioni O, et al. Isoniazid therapy in Parkinson’s disease. Mov Disord 1988; 3: 133–9PubMedGoogle Scholar
  258. 258.
    Laitinen LV, Bergenheim A, Hariz MI. Leksell’s posteroventral pallidotomy in the treatment of Parkinson’s disease. J Neurosurg 1992; 76: 53–61PubMedGoogle Scholar
  259. 259.
    Laitinen LV. Pallidotomy for Parkinson’s disease. Neurosurg Clin North Am 1995; 6: 105–12Google Scholar
  260. 260.
    Iacono RP, Shima F, Lonser RR, et al. The results, indications, and physiology of posteroventral pallidotomy for patients with Parkinson’s disease. Neurosurgery 1995; 36: 1118–25PubMedGoogle Scholar
  261. 261.
    Obeso JA, Grandas F, Vaamonde J, et al. Motor complications associated with chronic levodopa therapy in Parkinson’s disease. Neurology 1989; 39 Suppl. 2: 11–9PubMedGoogle Scholar
  262. 262.
    Muenter MD, Sharpless NS, Tyce GM, et al. Patterns of dystonia (‘I-D-I’ and ‘D-I-D’) in response to l-dopa therapy for Parkinson’s disease. Mayo Clin Proc 1977; 52: 163–74PubMedGoogle Scholar
  263. 263.
    Victor JF, Pollak P, Gervason CL, et al. Levodopa-induced diphasic dyskinesias improved by subcutaneous apomorphine. Mov Disord 1992; 7: 283–4Google Scholar
  264. 264.
    Durif F, Deffond D, Dordain G, et al. Apomorphine and diphasic dyskinesia. Clin Neuropharmacol 1994; 17: 99–102PubMedGoogle Scholar
  265. 265.
    Burke RE, Fahn S, Jankovic J, et al. Tardive dystonia: late onset and persistent dystonia caused by antipsychotic drugs. Neurology 1982; 32: 1335–46PubMedGoogle Scholar
  266. 266.
    Wojcik JD, Falk WE, Fink JS, et al. A review of 32 cases of tardive dystonia. Am J Psychiatry 1991; 148: 1055–9PubMedGoogle Scholar
  267. 267.
    Nasrallah HA, Churchill CM, Hamdan-Allan GA. Higher frequency of neuroleptic-induced dystonia in mania than in schizophrenia [letter]. Am J Psychiatry 1988; 145: 1455–6PubMedGoogle Scholar
  268. 268.
    Remington GJ, Voineskos G, Pollock B, et al. Prevalence of neuroleptic-induced dystonia in mania and schizophrenia. Am J Psychiatry 1990; 147: 1231–3PubMedGoogle Scholar
  269. 269.
    Khanna R, Das A, Damodaran SS. Prospective study of neuroleptic-induced dystonia in mania and schizophrenia. Am J Psychiatry 1992; 149: 511–3PubMedGoogle Scholar
  270. 270.
    Spina E, Sturiale V, Valvo S, et al. Prevalence of acute dystonic reactions associated with neuroleptic treatment with and without anticholinergic prophylaxis. Int Clin Psychopharmacol 1993; 8: 21–4PubMedGoogle Scholar
  271. 271.
    Aguilar EJ, Keshavan MS, Martínez-Quiles MD, et al. Predictors of acute dystonia in first-episode psychotic patients. Am J Psychiatry 1994; 151: 1819–21PubMedGoogle Scholar
  272. 272.
    Yassa R, Nair V, Dimitry R. Prevalence of tardive dystonia. Acta Psychiatr Scand 1986; 73: 629–33PubMedGoogle Scholar
  273. 273.
    Friedman JH, Kuchanski LT, Wagner RL. Tardive dystonia in a psychiatric hospital. J Neurol Neurosurg Psychiatry 1987; 50: 801–3PubMedGoogle Scholar
  274. 274.
    Sethi KD, Hess DC, Harp RJ. Prevalence of dystonia in veterans on chronic antipsychotic therapy. Mov Disord 1990; 5: 319–21PubMedGoogle Scholar
  275. 275.
    Chiu H, Shum P, Lau J, et al. Prevalence of tardive dyskinesia, tardive dystonia, and respiratory dyskinesia among Chinese psychiatric patients in Hong Kong. Am J Psychiatry 1992; 149: 1081–5PubMedGoogle Scholar
  276. 276.
    Sachdev P. Tardive and chronically recurrent oculogyric crises. Mov Disord 1993; 8: 93–7PubMedGoogle Scholar
  277. 277.
    Lu CS, Chu NS. Acute dystonic reaction with asterixis and myoclonus following metoclopramide therapy [letter]. J Neurol Neurosurg Psychiatry 1988; 51: 1002–3PubMedGoogle Scholar
  278. 278.
    Pérez N, Fernandez S, Legarda I, et al. Distonía aguda por neurolépticos en el tratamiento del vértigo: a propósito de dos casos. Acta Otorrinolaringol Esp 1992; 43: 287–9PubMedGoogle Scholar
  279. 279.
    Schott K, Ried S, Stevens I, et al. Neuroleptically-induced dystonia in Huntington’s disease: a case report. Eur Neurol 1989; 29: 39–40PubMedGoogle Scholar
  280. 280.
    Miller LG, Jankovic J. Sulpiride-induced tardive dystonia. Mov Disord 1990; 5: 83–4PubMedGoogle Scholar
  281. 281.
    Linazasoro G, Martí-Massó JF, Olasagasti B. Acute dystonia-induced by sulpiride. Clin Neuropharmacol 1991; 14: 463–4PubMedGoogle Scholar
  282. 282.
    Bucci KK, Haverstick DE, Abercrombie SA. Dystonic-like reaction following cisapride therapy. J Fam Pract 1995; 40: 86–8PubMedGoogle Scholar
  283. 283.
    Shafrir Y, Levy Y, Steinherz R. Acute dystonic reaction due to domperidone in a infant. Harefuah 1986; 110: 237–8PubMedGoogle Scholar
  284. 284.
    Bonuccelli U, Nocchiero A, Napolitano A, et al. Domperidone-induced acute dystonia and polycystic ovary syndrome. Mov Disord 1991; 6: 79–81PubMedGoogle Scholar
  285. 285.
    Gabellini AS, Pezzoli A, De-Massis P, et al. Veralipride-induced tardive dystonia in a patient with bipolar psychosis. Ital J Neurol Sci 1992; 13: 621–3PubMedGoogle Scholar
  286. 286.
    Kidron D, Melamed E. Forms of dystonia in patients with Parkinson’s disease. Neurology 1987; 37: 1009–11PubMedGoogle Scholar
  287. 287.
    McHale DM, Sage JI, Sonsalla PK, et al. Complex dystonia of Parkinson’s disease: clinical features and relation to plasma levodopa profile. Clin Neuropharmacol 1990; 13: 164–70PubMedGoogle Scholar
  288. 288.
    Mark MH, Sage JI. Levodopa-associated hemifacial dystonia. Mov Disord 1991; 6: 383PubMedGoogle Scholar
  289. 289.
    Poewe WH. Clinical aspects of motor fluctuations in Parkinson’s disease. Neurology 1994; 44 Suppl. 6: S6–9PubMedGoogle Scholar
  290. 290.
    Leiguarda R, Merello M, Sabe L, et al. Bromocriptine-induced dystonia in patients with aphasia and hemiparesis. Neurology 1999; 4: 219–22Google Scholar
  291. 291.
    Kramer MS, Marcus DJ, DiFerdinando J, et al. Atypical acute dystonia associated with trazodone treatment. J Clin Psy-chopharmacol 1986; 6: 117–8Google Scholar
  292. 292.
    Reccoppa L, Welch WA, Ware MR. Acute dystonia and fluoxetine [letter]. J Clin Psychiatry 1990; 51: 487PubMedGoogle Scholar
  293. 293.
    Boylan K. Persistent dystonia associated with buspirone. Neurology 1990; 40: 1904PubMedGoogle Scholar
  294. 294.
    Stoukides JA, Stoukides CA. Extrapyramidal symptoms upon discontinuation of fluoxetine [letter]. Am J Psychiatry 1991; 148: 126Google Scholar
  295. 295.
    Río J, Molins A, Viguera ML, et al. Distonia aguda por fluoxetina. Med Clin (Barc) 1992; 99: 46–7Google Scholar
  296. 296.
    George MS, Trimble MR. Dystonic reaction associated with fluvoxamine [letter]. J Clin Psychopharmacol 1993; 1: 220–1Google Scholar
  297. 297.
    Dave M. Fluoxetine-associated dystonia [letter]. Am J Psychiatry 1994; 151: 149PubMedGoogle Scholar
  298. 298.
    Shihabuddin L, Rapport D. Sertraline and extrapyramidal side effects [letter]. Am J Psychiatry 1994; 151: 288PubMedGoogle Scholar
  299. 299.
    Chong SA. Fluvoxamine and mandibular dystonia [letter]. Can J Psychiatry 1995; 40: 430–1PubMedGoogle Scholar
  300. 300.
    Lauterbach EC. Fluoxetine, buspirone, myoclonus, and dystonia [letter]. Am J Psychiatry 1995; 152: 1697PubMedGoogle Scholar
  301. 301.
    Hoaken PC. An alert to extrapyramidal side-effects from SSRIs [letter]. Can J Psychiatry 1995; 40: 51PubMedGoogle Scholar
  302. 302.
    Ornadel D, Barnes EA, Dick DJ. Acute dystonia due to amitryptiline [letter]. J Neurol Neurosurg Psychiatry 1992; 55:414PubMedGoogle Scholar
  303. 303.
    Lee HK. Dystonic reactions to amitriptyline and doxepin [letter]. Am J Psychiatry 1988; 145: 649PubMedGoogle Scholar
  304. 304.
    Pande AC, Max P. A dystonic reaction occurring during treatment with tranylcypromine [letter]. J Clin Psychopharmacol 1989; 9: 229–30PubMedGoogle Scholar
  305. 305.
    Jarecke CR, Reid PJ. Acute dystonic reaction-induced by a monoamine oxidase inhibitor. J Clin Psychopharmacol 1990; 10: 144–5PubMedGoogle Scholar
  306. 306.
    Critchley EM, Phillips M. Unusual idiosyncratic reactions to carbamazepine [letter]. J Neurol Neurosurg Psychiatry 1988; 51: 1238PubMedGoogle Scholar
  307. 307.
    Lee JW. Persistent dystonia associated with carbamazepine therapy: a case report. N Z Med J 1994; 107: 360–1PubMedGoogle Scholar
  308. 308.
    Soman P, Jain S, Rajsekhar V, et al. Dystonia: a rare manifestation of carbamazepine toxicity. Postgrad Med J 1994; 70: 54–5PubMedGoogle Scholar
  309. 309.
    Moss W, Ojukwu C, Chiriboga CA. Phenytoin-induced movement disorder. Unilateral presentation in a child and response to diphenhydramine. Clin Pediatr (Phila) 1994; 33: 364–8Google Scholar
  310. 310.
    Lacayo A, Mitra N. Report of a case of phénobarbital—induced dystonia [letter]. Clin Pediatr (Phila) 1992; 31: 252Google Scholar
  311. 311.
    Howrie DL, Rowley AH, Krenzelok EP Benztropine-induced acute dystonic reaction. Ann Emerg Med 1986; 15: 594–6PubMedGoogle Scholar
  312. 312.
    Le Witt PA, Walters A, Hening W, et al. Persistent movement disorders-induced by buspirone. Mov Disord 1993; 8: 331–4Google Scholar
  313. 313.
    Hooker EA, Danzl DF. Acute dystonic reaction due to diazepam. J Emerg Med 1988; 6: 491–3PubMedGoogle Scholar
  314. 314.
    Pérez-Trullen JM, Modrego-Pardo PJ, Vázquez-André M, et al. Bromazepam-induced dystonia. Biomed Pharmacother 1992; 46: 375–6PubMedGoogle Scholar
  315. 315.
    Stolarek IH, Ford MJ. Acute dystonia-induced by midazolam and abolished by flumazenil [letter]. BMJ 1990; 300: 614PubMedGoogle Scholar
  316. 316.
    Capstick C, Checkley S, Gray J, et al. Dystonia-induced by amphetamine and haloperidol [letter]. Br J Psychiatry 1994; 165: 276PubMedGoogle Scholar
  317. 317.
    Thiel A, Dressler D. Dyskinesias possibly-induced by norpseudo-ephedrine. J Neurol 1994; 241: 167–169PubMedGoogle Scholar
  318. 318.
    Gay CT, Ryan SG. Paroxysmal kinesigenic dystonia after methylphenidate administration. J Child Neurol 1994; 9: 45–6PubMedGoogle Scholar
  319. 319.
    Merab J. Acute dystonic reaction to cocaine [letter]. Am J Med 1988; 84: 564PubMedGoogle Scholar
  320. 320.
    Choy-Kwong M, Lipton RB. Dystonia related to cocaine withdrawal: a case report and pathogenic hypothesis. Neurology 1989; 39: 996–7PubMedGoogle Scholar
  321. 321.
    Kumor K. Cocaine withdrawal dystonia. Neurology 1990; 40: 863–4PubMedGoogle Scholar
  322. 322.
    Hegarty AM, Lipton RB, Merriam AE, et al. Cocaine as a risk factor for acute dystonic reactions. Neurology 1991; 41: 1670–2PubMedGoogle Scholar
  323. 323.
    Farrel PE, Diehl AK. Acute dystonic reaction to crack cocaine [letter]. Ann Emerg Med 1991; 20: 322Google Scholar
  324. 324.
    Merello MJ, Nogues MA, Leiguarda RC, et al. Dystonia and reflex sympathetic dystrophy-induced by ergotamine. Mov Disord 1991; 6: 263–4PubMedGoogle Scholar
  325. 325.
    Olson WL. Dystonia and reflex sympathetic dystrophy-induced by ergotamine. Mov Disord 1992; 7: 188–9PubMedGoogle Scholar
  326. 326.
    García G, Kaufman MB, Colucci RD. Dystonic reaction associated with sumatriptan [letter]. Ann Pharmacother 1994; 28: 1199PubMedGoogle Scholar
  327. 327.
    de Medina A, Biasini O, Rivera A, et al. Nifedipine and myoclonic dystonia [letter]. Ann Intern Med 1986; 104: 125PubMedGoogle Scholar
  328. 328.
    Casteels-Van-Daele M, Eggermont E, Casaer P, et al. Acute dystonic reactions and long-lasting impaired consciousness associated with oxatomide in children [letter]. Lancet 1986; I: 1204–5Google Scholar
  329. 329.
    Santora J, Rozek S, Sarnie MR. Diphenhydramine-induced dystonia [letter]. Clin Pharm 1989; 8: 471PubMedGoogle Scholar
  330. 330.
    Roila F, Donati D, Basurto C, et al. Diphenhydramine and acute dystonia [letter]. Ann Intern Med 1989; 111: 92–3PubMedGoogle Scholar
  331. 331.
    Etzel JV. Diphenhydramine-induced acute dystonia. Pharmacotherapy 1994; 14: 492–6PubMedGoogle Scholar
  332. 332.
    Romisher S, Felter R, Dougherty J. Tagamet-induced acute dystonia. Ann Emerg Med 1987; 16: 1162–4PubMedGoogle Scholar
  333. 333.
    McCann UD, Penetar DM, Belenky G. Acute dystonic reaction in normal humans caused by catecholamine depletion. Clin Neuropharmacol 1990; 13: 565–568PubMedGoogle Scholar
  334. 334.
    Shafrir Y, Levy Y, Beharab A, et al. Acute dystonic reaction to bethanechol: a direct acetylcholine receptor agonist. Dev Med Child Neurol 1986; 28: 646–8PubMedGoogle Scholar
  335. 335.
    Miller LG, Jankovic J. Persistent dystonia possibly-induced by flecainide. Mov Disord 1992; 7: 62–3PubMedGoogle Scholar
  336. 336.
    Achumba JI, Ette El, Thomas WO, et al. Chloroquine-induced acute dystonic reactions in the presence of metronidazole. Drug Intell Clin Pharm 1988; 22: 308–10PubMedGoogle Scholar
  337. 337.
    Ascher DP, Delaney RA. Acute dystonia from etoposide. Drug Intell Clin Pharm 1988; 22: 41–2PubMedGoogle Scholar
  338. 338.
    Mets B. Acute dystonia after alfentanil in untreated Parkinson’s disease [letter]. Anesth Analg 1991; 72: 557–8PubMedGoogle Scholar
  339. 339.
    Lamberti JS, Bellnier T. Clozapine and tardive dystonia. J Nerv Ment Dis 1993; 181: 137–8PubMedGoogle Scholar
  340. 340.
    Kastrup O, Gastpar M, Schwarz M. Acute dystonia due to clozapine. J Neurol Neurosurg Psychiatry 1994; 57: 119PubMedGoogle Scholar
  341. 341.
    Thomas P, Lalaux N, Vaiva G, et al. Dose-dependent stuttering and dystonia in a patient taking clozapine [letter]. Am J Psychiatry 1994; 151: 1096PubMedGoogle Scholar
  342. 342.
    Owens DG. Extrapyramidal side effects and tolerability of risperidone: a review. J Clin Psychiatry 1994; 55 Suppl: 29–35PubMedGoogle Scholar
  343. 343.
    Dickson R, Williams R, Dalby JT. Dystonic reaction and relapse with clozapine discontinuation and risperidone intiation [letter]. Can J Psychiatry 1994; 39: 184PubMedGoogle Scholar
  344. 344.
    Radford JM, Brown TM, Borison RL. Unexpected dystonia while changing from clozapine to risperidone [letter]. J Clin Psychopharmacol 1995; 15: 225–6PubMedGoogle Scholar
  345. 345.
    Worrall R, Wilson A, Cullen M. Dystonia and drug-induced hepatitis in a patient treated with clozapine [letter]. Am J Psychiatry 1995; 152: 647–8PubMedGoogle Scholar
  346. 346.
    Lupu V, Gheragosian G. Reactie distonica severa in intoxicatia acuta cu Torecan. Rev Pediatr Obstet Ginecol Pediatr 1989; 38: 277–81PubMedGoogle Scholar
  347. 347.
    Jiménez-Jiménez FJ, Vázquez A, García-Ruiz P, et al. Chronic hemidystonia following acute dystonic reaction to thiethyl-perazine [letter]. J Neurol Neurosurg Psychiatry 1991; 54: 562PubMedGoogle Scholar
  348. 348.
    Shimada J, Akama Y, Tase C, et al. Problems of epidural droperidol administration. Masui 1994; 43: 1248–50PubMedGoogle Scholar
  349. 349.
    Giménez-Roldán S, Mateo D, Bartolomé P. Tardive dystonia and severe tardive dyskinesia. Acta Psychiatr Scand 1985; 71: 488–94PubMedGoogle Scholar
  350. 350.
    Kang UJ, Burke RE, Fahn S. Natural history and treatment of tardive dystonia. Mov Disord 1986; 1: 193–208PubMedGoogle Scholar
  351. 351.
    Gardos GG, Cole JO, Salomon M, et al. Clinical forms of severe tardive dyskinesia. Am J Psychiatry 1987; 144: 895–902PubMedGoogle Scholar
  352. 352.
    Addonizio G, Alexopoulos GS. Drug-induced dystonia in young and elderly patients. Am J Psychiatry 1988; 145: 869–71PubMedGoogle Scholar
  353. 353.
    Yassa R, Nair V, Iskandar H. A comparison of severe tardive dystonia and severe tardive dyskinesia. Acta Psychiatr Scand 1989; 80: 155–9PubMedGoogle Scholar
  354. 354.
    Bosch MF, Ludin HP. Apomorphin als adjuvante behandlung beim idiopathischen parkinsonsyndrom. Schweiz Arch Neurol Psychiatr 1994; 145: 8–13PubMedGoogle Scholar
  355. 355.
    Poewe WH, Lees AJ. The pharmacology of foot dystonia in parkinsonism. Clin Neuropharmacol 1987; 10: 47–56PubMedGoogle Scholar
  356. 356.
    Pacchetti C, Albani G, Martignoni E, et al. ‘Off’ painful dystonia in Parkinson’s disease treated with botulinum toxin. Mov Disord 1995; 10: 333–6PubMedGoogle Scholar
  357. 357.
    Tolosa E, Alom J, Martí MJ. Drug-induced dyskinesias. In: Jankovic J, Tolosa E, editors. Parkinson’s disease and movement disorders. 2nd ed. Baltimore: William & Wilkins, 1993: 375–97Google Scholar
  358. 358.
    Faurbye A, Rasch PJ, Peterson PB, et al. Neurological symptoms in pharmacotherapy of psychoses. Acta Psychiatr Scand 1964; 40: 10–27PubMedGoogle Scholar
  359. 359.
    Llau ME, Senard JM, Rascol O, et al. Mouvements anormaux d’origine médicamenteuse: l’expérience d’un centre de phar-macovigilance sur cinq ans. Therapie 1995; 50: 425–7PubMedGoogle Scholar
  360. 360.
    Kolakowska T, Williams AO, Ardern M, et al. Tardive dyskinesia in schizophrenics under 60 years of age. Biol Psychiatry 1986; 21: 161–9PubMedGoogle Scholar
  361. 361.
    Morgenstern H, Glazer WM, Gibowski LD, et al. Predictors of tardive dyskinesia: results of a cross-sectional study in an outpatient population. J Chronic Dis 1987; 40: 319–27PubMedGoogle Scholar
  362. 362.
    Gureje O. Tardive dyskinesia in schizophrenics. Prevalence, distribution and relationship to neurological ‘soft’ signs in Nigerian patients. Acta Psychiatr Scand 1987; 76: 523–8PubMedGoogle Scholar
  363. 363.
    Chouinard G, Annable L, Ross-Chouinard A, et al. A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. J Clin Psychopharmacol 1988; 8 (4 Suppl.):21S–6SPubMedGoogle Scholar
  364. 364.
    Bourgeois M. Les dyskinesies tardives des neuroleptiques en France. Encéphale 1988; 14 Spec No: 195-201Google Scholar
  365. 365.
    Moussaoui D, Douki S, Bentounsi B, et al. Epidemiologie des dyskinesies tardives au Maghreb. Encephale 1988; 14 Spec No: 203-8Google Scholar
  366. 366.
    Ko GN, Zhang LD, Yan WW, et al. The Shanghai 800: prevalence of tardive dyskinesia in a Chinese psychiatric hospital. Am J Psychiatry 1989; 146: 387–9PubMedGoogle Scholar
  367. 367.
    Yassa R, Nair NP, Iskander H, et al. Factors in the development of severe forms of tardive dyskinesia. Am J Psychiatry 1990; 147: 1156–63PubMedGoogle Scholar
  368. 368.
    Altamura AC, Cavallaro R, Regazzetti MG. Prevalence and risk factors for tardive dyskinesia: a study in an Italian population of chronic schizophrenics. Eur Arch Psychiatry Neurol Sci 1990; 240: 9–12Google Scholar
  369. 369.
    Tan CH, Tay LK. Tardive dyskinesia in elderly psychiatric patients in Singapore. Aust N Z J Psychiatry 1991; 25: 119–22PubMedGoogle Scholar
  370. 370.
    Inada T, Ohnishi K, Kamisada M, et al. A prospective study of tardive dyskinesia in Japan. Eur Arch Psychiatry Clin Neurosci 1991; 240: 250–4PubMedGoogle Scholar
  371. 371.
    Sramek J, Roy S, Ahrens T, et al. Prevalence of tardive dyskinesia among three ethnic groups of chronic psychiatric patients. Hosp Community Psychiatry 1991; 42: 590–2PubMedGoogle Scholar
  372. 372.
    Richardson MA, Haugland G, Craig TJ. Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients. Am J Psychiatry 1991; 148: 1322–8PubMedGoogle Scholar
  373. 373.
    Saltz BL, Woerner MG, Kane JM, et al. Prospective study of tardive dyskinesia incidence in the elderly. JAMA 1991; 266: 2402–6PubMedGoogle Scholar
  374. 374.
    Yassa R, Nastase C, Dupont D, et al. Tardive dyskinesia in elderly psychiatric patients: a 5-year study. Am J Psychiatry 1992; 149: 1206–11PubMedGoogle Scholar
  375. 375.
    Sweet RA, Mulsant BH, Rifai AH, et al. Dyskinesia and neuroleptic exposure in elderly psychiatric inpatients. J Geriatr Psychiatry Neurol 1992; 5: 156–61PubMedGoogle Scholar
  376. 376.
    Koshino Y, Madokoro S, Ito T, et al. A survey of tardive dyskinesia in psychiatric inpatients in Japan. Clin Neuropharmacol 1992; 15: 34–43PubMedGoogle Scholar
  377. 377.
    McCreadie RG. The Nithsdale schizophrenia surveys. An overview. Soc Psychiatry Psychiatr Epidemiol 1992; 27: 40–5PubMedGoogle Scholar
  378. 378.
    Harris MJ, Panton D, Caligiuri MP, et al. High incidence of tardive dyskinesia in older outpatients on low doses of neu-roleptics. Psychopharmacol Bull 1992; 28: 87–92PubMedGoogle Scholar
  379. 379.
    Chiu HF, Wing YK, Kwong PK, et al. Prevalence of tardive dyskinesia in samples of elderly people in Hong Kong. Acta Psychiatr Scand 1993; 87: 266–8PubMedGoogle Scholar
  380. 380.
    Jeste DV, Caligiuri MP. Tardive dyskinesia. Schizophr Bull 1993; 19: 303–15PubMedGoogle Scholar
  381. 381.
    Sweet RA, Mulsant BH, Gupta B, et al. Duration of neuroleptic treatment and prevalence of tardive dyskinesia in late life. Arch Gen Psychiatry 1995; 52: 478–86PubMedGoogle Scholar
  382. 382.
    Miller CH, Simioni I, Oberbauer H, et al. Tardive dyskinesia prevalence rates during a ten-year follow-up. J Nerv Ment Dis 1995; 183: 404–7PubMedGoogle Scholar
  383. 383.
    Dorevitch A, Meretyk I, Umansky Y, et al. Antipsychotic drugs and tardive dyskinesia: preliminary results in an adolescent psychiatric ward. J Clin Pharm Ther 1995; 20: 63–5PubMedGoogle Scholar
  384. 384.
    Jeste DV, Caligiuri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 1995; 52: 756–65PubMedGoogle Scholar
  385. 385.
    Ahlfors UG, Rimon R, Appelberg B, et al. Remoxipride and haloperidol in schizophrenia: a double-blind multicentre study. Acta Psychiatr Scand 1990; 358 Suppl.: 99–103Google Scholar
  386. 386.
    Walinder J, Holm AC. Experiences of long-term treatment with remoxipride: efficacy and tolerability. Acta Psychiatr Scand Suppl 1990; 358: 158–63PubMedGoogle Scholar
  387. 387.
    Kane JM, Woerner MG, Pollack S, et al. Does clozapine cause tardive dyskinesia? J Clin Psychiatry 1993; 54: 327–30PubMedGoogle Scholar
  388. 388.
    Tamminga CA, Thaker GK, Moran M, et al. Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry 1994; 55 Suppl. B: 102–6PubMedGoogle Scholar
  389. 389.
    Dave N. Clozapine-related tardive dyskinesia. Biol Psychiatry 1994; 35: 886–7PubMedGoogle Scholar
  390. 390.
    Addington DE, Toews JA, Addington JM. Risperidone and tardive dyskinesia: a case report [letter]. J Clin Psychiatry 1995; 56: 484–5PubMedGoogle Scholar
  391. 391.
    Beuclair L, Fontaine R. Tardive dyskinesia associated with metoclopramide. Can Med Assoc J 1986; 134: 613–4Google Scholar
  392. 392.
    Lazzara RR, Stoudemire A, Manning D, et al. Metoclopramide-induced tardive dyskinesia: a case report. Gen Hosp Psychiatry 1986; 8: 107–9PubMedGoogle Scholar
  393. 393.
    Patel M, Louis S. Long-term neurologic complications of metoclopramide [letter]. N Y State J Med 1986; 86: 210PubMedGoogle Scholar
  394. 394.
    Breitbart W. Tardive dyskinesia associated with high-dose intravenous metoclopramide [letter]. N Engl J Med 1986; 315: 518–9PubMedGoogle Scholar
  395. 395.
    Mahler Jr JC, Brown RP. More on metoclopramide and tardive dyskinesia [letter]. N Engl J Med 1987; 316: 412–3PubMedGoogle Scholar
  396. 396.
    Sewell DD, Jeste DV. Metoclopramide-associated tardive dyskinesia. An analysis of 67 cases. Arch Fam Med 1992; 1: 271–8PubMedGoogle Scholar
  397. 397.
    Sewell DD, Yoshinobu BH, Caligiuri MP, et al. Metoclopramide-associated tardive dyskinesia in hemodialysis patients with diabetes mellitus. Two case reports. Gen Hosp Psychiatry 1992; 14: 416–9PubMedGoogle Scholar
  398. 398.
    Putnam PE, Orenstein SR, Wessel HB, et al. Tardive dyskinesia associated with use of metoclopramide in a child. J Pediatr 1992; 121: 983–5PubMedGoogle Scholar
  399. 399.
    Sewell DD, Kodsi AB, Caligiuri MP, et al. Metoclopramide and tardive dyskinesia. Biol Psychiatry 1994; 36: 630–2PubMedGoogle Scholar
  400. 400.
    Robinson D, Omar SJ, Dangel C, et al. Metoclopramide-in-duced extrapyramidal symptoms in a diabetic patient [letter]. J Am Geriatr Soc 1994; 42: 1307–8PubMedGoogle Scholar
  401. 401.
    Macucci M, Dotti MT, Federico A. Familial acute dystonic-dyskinetic syndrome with dominant inheritance after use of antidopaminergic antiemetic drugs. Mov Disord 1995; 10: 528–9PubMedGoogle Scholar
  402. 402.
    Assmann VC, Perquin WV, Touw DJ. Extrapyramidal movement disorders following the use of flunarizine. Ned Tijdschr Geneeskd 1988; 12: 1940–3Google Scholar
  403. 403.
    Sandyk R. Tardive dyskinesia-induced by sulpiride in a patient with hypothyroidism. Clin Neuropharmacol 1986; 9: 100–1PubMedGoogle Scholar
  404. 404.
    Achiron A, Zoldan Y, Melamed E. Tardive dyskinesia-induced by sulpiride. Clin Neuropharmacol 1990; 13: 248–52PubMedGoogle Scholar
  405. 405.
    Masmoudi K, Decocq G, Chetaille E, et al. Troubles extrapyramidaux induits par le veralipride (Agreal). A propos de cinq observations. Therapie 1995; 50: 451–4PubMedGoogle Scholar
  406. 406.
    Huang CC. Persistent tardive dyskinesia associated with amox-apine therapy [letter]. Am J Psychiatry 1986; 143: 1069–70PubMedGoogle Scholar
  407. 407.
    Huang CC. Persistent tardive dyskinesia associated with amoxapine therapy: two case reports. Hillside J Clin Psychiatry 1986; 8: 209–13PubMedGoogle Scholar
  408. 408.
    Gangat AE, Luiz HA, Kajee AH, et al. Tricyclic-induced acute tardive dyskinesia: a case report [letter]. S Afr Med J 1987; 71:729PubMedGoogle Scholar
  409. 409.
    Yassa R, Camille Y, Belzile L. Tardive dyskinesia in the course of antidepressant therapy: a prevalence study and review of the literature. J Clin Psychopharmacol 1987; 7: 243–6PubMedGoogle Scholar
  410. 410.
    Otani K, Kaneko S, Fukushima Y, et al. Involuntary movements associated with mianserin treatment: a case report [letter]. Br J Psychiatry 1989; 154: 113–4PubMedGoogle Scholar
  411. 411.
    Golden RN, Miller H, Evans DL. Trimipramine and dopamine receptor blockade [letter]. J Clin Psychiatry 1989; 50: 392–3PubMedGoogle Scholar
  412. 412.
    Katz SE. Tardive dyskinesia associated with molindone treatment [letter]. Am J Psychiatry 1990; 147: 124–5PubMedGoogle Scholar
  413. 413.
    Sparring-Bjorksten K, Walinder J. Does mianserin induce involuntary movements in brain damaged patients? Int Clin Psychopharmacol 1993; 8: 203–4PubMedGoogle Scholar
  414. 414.
    Gersten SP. Tardive dyskinesia-like syndromes with clomipramine [letter]. Am J Psychiatry 1993; 150: 165–6PubMedGoogle Scholar
  415. 415.
    Budman CL, Bruun RD. Persistent dyskinesia in a patient receiving fluoxetine [letter]. Am J Psychiatry 1991; 148: 1403PubMedGoogle Scholar
  416. 416.
    al-Adwani A. Brain damage and tardive dyskinesia [letter]. Br J Psychiatry 1995; 167: 410–1PubMedGoogle Scholar
  417. 417.
    Wils V. Extrapyramidal symptoms in a patient treated with fluvoxamine [letter]. J Neurol Neurosurg Psychiatry 1992; 55: 330–1PubMedGoogle Scholar
  418. 418.
    Arya DK, Szabadi E. Dyskinesia associated with fluvoxamine. J Clin Psychopharmacol 1993; 13: 365–6PubMedGoogle Scholar
  419. 419.
    Sternbach H, Jordan S. Lithium-associated tardive dyskinesia. J Clin Psychopharmacol 1990; 10: 143–4PubMedGoogle Scholar
  420. 420.
    Lazarus A. Tardive dyskinesia-like syndrome associated with lithium and carbamazepine. J Clin Psychopharmacol 1994; 14: 146–7PubMedGoogle Scholar
  421. 421.
    Ghadirian AM, Annable L, Belanger MC, et al. A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients. J Clin Psychiatry 1996; 57: 22–8PubMedGoogle Scholar
  422. 422.
    Strauss A. Oral dyskinesia associated with buspirone use in an elderly woman [letter]. J Clin Psychiatry 1988; 49: 322–3PubMedGoogle Scholar
  423. 423.
    Simpson GM, Singh H. Buspirone and dyskinesia [letter]. J Clin Psychiatry 1988; 49: 50Google Scholar
  424. 424.
    Lydiard RB. Buspirone revisited [letter]. J Clin Psychiatry 1989; 50: 308PubMedGoogle Scholar
  425. 425.
    Rock NL. Possible adverse effects of buspirone when used with other psychotropic drugs. J Clin Psychopharmacol 1990; 10: 80–1Google Scholar
  426. 426.
    Sandyk R. Orofacial dyskinesias associated with lorazepam therapy. Clin Pharm 1986; 5: 419–21PubMedGoogle Scholar
  427. 427.
    Sexson WR, Thigpen J, Stajich GV. Stereotypic movements after lorazepam administration in premature neonates: a series and review of the literature. J Perinatol 1995; 15: 146–149PubMedGoogle Scholar
  428. 428.
    Dooley J, Camfield P, Buckley D, et al. Methsuximide-induced movement disorder. Pediatrics 1991; 88: 1291–2PubMedGoogle Scholar
  429. 429.
    Hauser RA, Olanow CW. Orobuccal dyskinesia associated with trihexyphenidyl therapy in a patient with Parkinson’s disease. Mov Disord 1993; 8: 512–4PubMedGoogle Scholar
  430. 430.
    Linazasoro G. Anticholinergics and dyskinesia [letter]. Mov Disord 1994; 9: 689PubMedGoogle Scholar
  431. 431.
    Morisy L, Platt D. Hazards of high-dose meperidine [letter]. JAMA 1986; 255: 467–8PubMedGoogle Scholar
  432. 432.
    Merriam AE. Pemoline-induced abnormal involuntary movements. J Clin Psychopharmacol 1990; 10: 302–3PubMedGoogle Scholar
  433. 433.
    Schuller DE, Turkewitz D. Adverse effects of antihistamines. Postgrad Med 1986; 79: 75–86PubMedGoogle Scholar
  434. 434.
    Micheli F, Gatto E, Gene R, et al. Clenbuterol-induced tardive dyskinesia. Clin Neuropharmacol 1991; 14: 427–31PubMedGoogle Scholar
  435. 435.
    Ramsay FM, Millard PH. Tardive dyskinesia in the elderly. Age Ageing 1986; 15: 145–50PubMedGoogle Scholar
  436. 436.
    Morgenstern H, Glazer WM, Niedzwiecki D, et al. The impact of neuroleptic medication on tardive dyskinesia: a meta-anal-ysis of published studies. Am J Public Health 1987; 77: 717–24PubMedGoogle Scholar
  437. 437.
    Wolf ME, De Wolfe AS, Mosnaim AD. Risk factors for tardive dyskinesia according to primary psychiatric diagnosis. Hillside J Clin Psychiatry 1987; 9: 3–11PubMedGoogle Scholar
  438. 438.
    Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull 1992; 18: 701–15PubMedGoogle Scholar
  439. 439.
    Muscettola G, Pampallona S, Barbato G, et al. Persistent tardive dyskinesia: demographic and pharmacological risk factors. Acta Psychiatr Scand 1993; 87: 29–36PubMedGoogle Scholar
  440. 440.
    Ganzini L, Heintz RT, Hoffman WF, et al. The prevalence of tardive dyskinesia in neuroleptic-treated diabetics. A controlled study. Arch Gen Psychiatry 1991; 48: 259–63PubMedGoogle Scholar
  441. 441.
    Ganzini L, Casey DE, Hoffman WF, et al. Tardive dyskinesia and diabetes mellitus. Psychopharmacol Bull 1992; 28: 281–6PubMedGoogle Scholar
  442. 442.
    Woerner MG, Saltz BL, Kane JM, et al. Diabetes and development of tardive dyskinesia. Am J Psychiatry 1993; 150: 966–88PubMedGoogle Scholar
  443. 443.
    Pourcher E, Baruch R, Bouchard RH, et al. Neuroleptic associated tardive dyskinesias in young people with psychoses. Br J Psychiatry 1995; 166: 768–72PubMedGoogle Scholar
  444. 444.
    Ueyama K, Fukuzako H, Takeuchi K, et al. Brain atrophy and intellectual impairment in tardive dyskinesia. Jpn J Psychiatry Neurol 1993; 47: 99–104PubMedGoogle Scholar
  445. 445.
    Dinan TG, Kohen D. Tardive dyskinesia in bipolar affective disorder: relationship to lithium therapy. Br J Psychiatry 1989; 155: 55–7PubMedGoogle Scholar
  446. 446.
    Waddington JL, Youssef HA. An unusual cluster of tardive dyskinesia in schizophrenia: association with cognitive dysfunction and negative symptoms. Am J Psychiatry 1986; 143: 1162–5PubMedGoogle Scholar
  447. 447.
    Dixon L, Weiden PJ, Haas G, et al. Increased tardive dyskinesia in alcohol-abusing schizophrenic patients. Compr Psychiatry 1992; 33: 121–2PubMedGoogle Scholar
  448. 448.
    Yassa R, Nair V, Schwartz G. Early versus late onset psychosis and tardive dyskinesia. Biol Psychiatry 1986; 21: 1291–7PubMedGoogle Scholar
  449. 449.
    Yassa R. Tardive dyskinesia and anticholinergic drugs. A critical review of the literature. Encephale 1988; 14 Spec No: 233-9Google Scholar
  450. 450.
    Cavallaro R, Smeraldi E. Antipsychotic-induced tardive dyskinesia: recognition, prevention and management. CNS Drugs 1995; 4: 278–293Google Scholar
  451. 451.
    Obeso JA, Artieda J, Marsden CD. Different clinical presentations of myoclonus. In: Jankovic J, Tolosa E, editors. Parkinson’s disease and movement disorders, 2nd ed. Baltimore: Williams & Wilkins: 315–28Google Scholar
  452. 452.
    Forstl H, Pohlmann-Eden B, Rothenberger A. Veranderungen somatosensibel evozierter Potentiale bei pharmakogener Myoklonie. Nervenarzt 1992; 63: 359–62PubMedGoogle Scholar
  453. 453.
    Brogmus KE, Lesch A. Psychopharmakainduzierte Myo-klonien. Psychiatr Prax 1995; 22: 77–9PubMedGoogle Scholar
  454. 454.
    Drouet A, Valance J. Myoclonies de repos et d’action induites par la piperazine. Rev Med Interne 1994; 15: 364–5PubMedGoogle Scholar
  455. 455.
    Tominaga H, Fukuzako H, Izumi K, et al. Tardive myoclonus [letter]. Lancet 1987; I: 322Google Scholar
  456. 456.
    Fukuzako H, Tominaga H, Izumi K, et al. Postural myoclonus associated with long-term administration of neuroleptics in schizophrenic patients. Biol Psychiatry 1990; 27: 1116–26PubMedGoogle Scholar
  457. 457.
    Little JT, Jankovic J. Tardive myoclonus. Mov Disord 1987; 2: 307–11PubMedGoogle Scholar
  458. 458.
    Noble J, Matthew H. Acute poisoning by tricyclic antidepressants: clinical features and management of 100 patients. Clin Toxicol 1969; 2: 403–21Google Scholar
  459. 459.
    Burks JS, Walker JE, Rumack BH, et al. Tricyclic antidepressant poisoning; reversal of coma, choreoathetosis and myoclonus by physostigmine. JAMA 1974; 230: 1405–7PubMedGoogle Scholar
  460. 460.
    Darcourt G, Fadeuilhe A, Lavagna J, et al. Trois cas de myoclonies d’action au cors de traitements par l’imipramine et l’amitriptyline. Rev Neurol (Paris) 1970; 122: 141–2Google Scholar
  461. 461.
    Lippmann S, Moskovitz R, O’Tuama L. Tricyclic-induced myoclonus [letter]. Am J Psychiatry 1977; 134: 90–1PubMedGoogle Scholar
  462. 462.
    Garvey MJ, Tollefson GD. Occurrence of myoclonus in patients treated with cyclic antidepressants. Arch Gen Psychiatry 1987; 44: 269–72PubMedGoogle Scholar
  463. 463.
    Casas M, García-Ribera C, Alvarez E, et al. Myoclonic movements as a side-effect of treatment with therapeutic doses of clomipramine. Int Clin Psychopharmacol 1987; 2: 333–6PubMedGoogle Scholar
  464. 464.
    Devanand DP, Sackeim HA, Brown RP. Myoclonus during combined tricyclic antidepressant and lithium treatment. J Clin Psychopharmacol 1988; 8: 446–7PubMedGoogle Scholar
  465. 465.
    Fukuzako H, Hokazono Y, Tominaga H, et al. Jerk-locked averaging and somatosensory evoked potential in tricyclic-induced myoclonus: a case report. Jpn J Psychiatry Neurol 1989; 43: 645–9PubMedGoogle Scholar
  466. 466.
    Forstl H, Pohlmann-Eden B. Amplitudes of somatosensory evoked potentials reflect cortical hyperexcitability in antide-pressant-induced myoclonus. Neurology 1990; 40: 924–6PubMedGoogle Scholar
  467. 467.
    Patterson JF. Myoclonus caused by a tricyclic antidepressant. South Med J 1990; 83: 463–5PubMedGoogle Scholar
  468. 468.
    Lejoyeux M, Ades J, Rouillon F. Myoclonies chez les patients traites par antidépresseurs tricycliques. Evaluation prospective [letter]. Presse Med 1994; 23: 447PubMedGoogle Scholar
  469. 469.
    Black KJ, Kilzieh N. Severe imipramine-induced myoclonus in a patient with psychotic bipolar depression, catatonia, and schizencephaly. Ann Clin Psychiatry 1994; 6: 45–9PubMedGoogle Scholar
  470. 470.
    Patel HC, Bruza D, Yeragani V. Myoclonus with trazodone [letter]. J Clin Psychopharmacol 1988; 8: 152PubMedGoogle Scholar
  471. 471.
    Feighner JP, Boyer WF, Tyler DL, et al. Adverse consequences of fluoxetine-MAOI combination therapy. J Clin Psychiatry 1990; 51: 222–5PubMedGoogle Scholar
  472. 472.
    Goldberg RJ, Huk M. Serotonin syndrome from trazodone and buspirone [letter]. Psychosomatics 1992; 33: 235–6PubMedGoogle Scholar
  473. 473.
    Jahr JS, Pisto JD, Gitlin MC, et al. The serotonin syndrome in a patient receiving sertraline after an ankle block. Anesth Analg 1994; 79: 189–91PubMedGoogle Scholar
  474. 474.
    Lauterbach EC. Reversible intermittent rhythmic myoclonus with fluoxetine in presumed Pick’s disease. Mov Disord 1994; 9: 343–6PubMedGoogle Scholar
  475. 475.
    White PD. Myoclonus and episodic delirium associated with phenelzine: a case report [letter]. J Clin Psychiatry 1987; 48: 340–1PubMedGoogle Scholar
  476. 476.
    Naylor MW, Grunhaus L, Cameron O. Myoclonic seizures after abrupt withdrawal from phenelzine and alprazolam. J Nerv Ment Dis 1987; 175: 111–4PubMedGoogle Scholar
  477. 477.
    Askenasy JJ, Yahr MD. Is monoamine oxidase inhibitor-induced myoclonus serotoninergically mediated? J Neural Transm 1988; 72: 67–76PubMedGoogle Scholar
  478. 478.
    Klawans HL, Goetz C, Bergen D. Levodopa-induced myoclonus. Arch Neurol 1975; 32: 331–4Google Scholar
  479. 479.
    Hirschorn KA, Greenberg HS. Successful treatment of levodopa-induced myoclonus and levodopa withdrawal-induced neuroleptic malignant syndrome. A case report. Clin Neuropharmacol 1988; 11: 278–81PubMedGoogle Scholar
  480. 480.
    Glantz R, Weiner WJ, Goetz CG, et al. Drug-induced asterixis in Parkinson’s disease. Neurology 1982; 2: 553–5Google Scholar
  481. 481.
    Goule JP, Husson A, Fondimare A, et al. Encéphalopatie aux sels insolubles de bismuth [letter]. Nouv Presse Med 1975; 4: 1366PubMedGoogle Scholar
  482. 482.
    Buge A, Rancurel G, Dechy H. Encéphalopathies myocloniques bismuthiques. Formes évolutives, complications tardives, durables ou définitives. A propos de 41 cases. Rev Neurol (Paris) 1977; 133: 401–15Google Scholar
  483. 483.
    Nogué S, Más A, Parés A, et al. Encefalopatfa mioclónica y convulsiva por bismuto. Utilidad del tratamiento con dimercaprol. Med Clin (Barc) 1985; 84: 530–2Google Scholar
  484. 484.
    Vidailhet M, Le TH, Wechsler B, et al. L’encephalopathie au bismuth n’a pas disparu... [letter]. Presse Med 1987; 16: 1054PubMedGoogle Scholar
  485. 485.
    Molina JA, Calandre L, Bermejo F. Myoclonic encephalopathy due to bismuth salts: treatment with dimercaprol and analysis of CSF transmitters. Acta Neurol Scand 1989; 79: 200–3PubMedGoogle Scholar
  486. 486.
    Gómez-Jiménez J, Alvarez J, Boada-Rovira M, et al. Encelafopatía mioclönica por bismuto [letter]. Rev Clin Esp 1989; 184:212PubMedGoogle Scholar
  487. 487.
    Molina JA, Calandre L, Bermejo F, et al. Encefalopatfa mioclónica por sales de bismuto. Eficacia del tratamiento con dimercaprol. Med Clin (Barc) 1989; 93: 20–2Google Scholar
  488. 488.
    Mendelowitz PC, Hoffman RS, Weber S. Bismuth absorption and myoclonic encephalopathy during bismuth subsalicylate therapy [letter]. Ann Intern Med 1990; 112: 140–1PubMedGoogle Scholar
  489. 489.
    Nogue-Xarau S, Sánz-Gallen P. Encefalopatfa mioclónica por bismuto [letter]. Rev Clin Esp 1990; 186: 145PubMedGoogle Scholar
  490. 490.
    Jungreis AC, Schaumburg HH. Encephalopathy from abuse of bismuth subsalicylate (Pepto-Bismol). Neurology 1993; 43: 1265PubMedGoogle Scholar
  491. 491.
    Gordon MF, Abrams RI, Rubin DB, et al. Bismuth subsalicylate toxicity as a cause of prolonged encephalopathy with myoclonus. Mov Disord 1995; 10: 220–2PubMedGoogle Scholar
  492. 492.
    Klawans HL, Carvey PM, Tanner CM, et al. Drug-induced myoclonus. Adv Neurol 1986; 43: 251–64PubMedGoogle Scholar
  493. 493.
    Aguglia U, Zappia M, Quattrone A. Carbamazepine-induced nonepileptic myoclonus in a child with benign epilepsy. Epilepsia 1987; 28: 515–8PubMedGoogle Scholar
  494. 494.
    Dhuna A, Pascual-Leone A, Talwar D. Exacerbation of partial seizures and onset of nonepileptic myoclonus with carbamazepine. Epilepsia 1991; 2: 275–8Google Scholar
  495. 495.
    Aguglia U, Gambardella A, Zappia M, et al. Negative myoclonus during valproate-related stupor. Neurophysiological evidence of a cortical non-epileptic origin. Electroencephalogr Clin Neurophysiol 1995; 94: 103–8PubMedGoogle Scholar
  496. 496.
    Lemus CZ, Lieberman JA, Johns CA. Myoclonus during treatment with clozapine and lithium: the role of serotonin. Hillside J Clin Psychiatry 1989; 11: 127–30PubMedGoogle Scholar
  497. 497.
    Rosen PD, Stevens R. Action myoclonus in lithium toxicity. Ann Neurol 1983; 13: 221–2PubMedGoogle Scholar
  498. 498.
    Julius SC, Brenner RP. Myoclonic seizures with lithium. Biol Psychiatry 1987; 22: 1184–90PubMedGoogle Scholar
  499. 499.
    Prettyman R. Lithium neurotoxicity at subtherapeutic serum levels [letter]. Br J Psychiatry 1994; 164: 123PubMedGoogle Scholar
  500. 500.
    Glavina MJ, Robertshaw R. Myoclonic spasms following intrathecal morphine. Anaesthesia 1988; 43: 389–90PubMedGoogle Scholar
  501. 501.
    Potter JM, Reid DB, Shaw RJ, et al. Myoclonus associated with treatment with high doses of morphine: the role of supplemental drugs. BMJ 1989; 299: 150–3PubMedGoogle Scholar
  502. 502.
    Jayawardena B, Hill DJ. Myoclonic spasms after epidural diamorphine infusion. Anaesthesia 1991; 46: 473–4PubMedGoogle Scholar
  503. 503.
    De Conno F, Caraceni A, Martíni C, et al. Hyperalgesia and myoclonus with intrathecal infusion of high-dose morphine. Pain 1991; 47: 337–9PubMedGoogle Scholar
  504. 504.
    Franco ML, Berro MJ, Sáez JM, et al. Mioclonías de miembros inferiores como complicación de la morfina espinal. Rev Esp Anestesiol Reanim 1992; 39: 192–3PubMedGoogle Scholar
  505. 505.
    Sjogren P, Jonsson T, Jensen NH, et al. Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine. Pain 1993; 55: 93–7PubMedGoogle Scholar
  506. 506.
    Cartwright PD, Hesse C, Jackson AO. Myoclonic spasms following intrathecal diamorphine. J Pain Symptom Manage 1993; 8: 492–5PubMedGoogle Scholar
  507. 507.
    de Armendi AJ, Fahey M, Ryan JF. Morphine-induced myoclonic movements in a pediatrie pain patient. Anesth Analg 1993; 77: 191–2PubMedGoogle Scholar
  508. 508.
    Bowdle TA, Rooke GA. Postoperative myoclonus and rigidity after anesthesia with opioids. Anesth Analg 1994; 78: 783–6PubMedGoogle Scholar
  509. 509.
    Kloke M, Bingel U, Seeber S. Complications of spinal opioid therapy: myoclonus, spastic muscle tone and spinal jerking. Support Care Cancer 1994; 2: 249–52PubMedGoogle Scholar
  510. 510.
    Jacobsen LS, Olsen AK, Sjogren P, et al. Morphine-induced hyperalgesia, allodynia and myoclonus: new side-effects of morphine? Ugeskr Laeger 1995; 157: 3307–10PubMedGoogle Scholar
  511. 511.
    Meloni G, Raucci U, Pinto RM, et al. Pretransplant conditioning with busulfan and cyclophosphamide in acute leukemia patients: neurological and electroencephalographic prospective study. Ann Oncol 1992; 3: 145–8PubMedGoogle Scholar
  512. 512.
    Martín M, Díaz-Rubio E, Casado A, et al. Prednimustine-in-duced myoclonus: a report of three cases. Acta Oncol 1994; 33: 81–2PubMedGoogle Scholar
  513. 513.
    Ammenti A, Reither B, Muller-Wiefel DE. Chlorambucil neurotoxicity: report of two cases. Helv Paediatr Acta 1980; 35: 281–7PubMedGoogle Scholar
  514. 514.
    Byrne TN Jr, Moseley TAE III, Finer MA. Myoclonic seizures following chlorambucil overdose. Ann Neurol 1981; 9: 191–4PubMedGoogle Scholar
  515. 515.
    LaDelfa I, Bayer N, Myers R, et al. Chlorambucil-induced myoclonic seizures in an adult. J Clin Oncol 1985; 3: 1691–2PubMedGoogle Scholar
  516. 516.
    Buchman AS, Bennett DA, Goetz CG. Bromocriptine-induced myoclonus. Neurology 1987; 37: 885PubMedGoogle Scholar
  517. 517.
    Ritchie EC, Bridenbaugh RH, Jabbari B. Acute generalized my-oclonus following buspirone administration. J Clin Psychiatry 1988; 49: 242–3PubMedGoogle Scholar
  518. 518.
    Lee DS, Wong HA, Knoppert DC. Myoclonus associated with lorazepam therapy in very-low-birth-weight infants. Biol Ne-onate 1994; 66: 311–5Google Scholar
  519. 519.
    Magny JF, d’Allest AM, Nedelcoux H, et al. Midazolam and myoclonus in neonate. Eur J Pediatr 1994; 15: 389–90Google Scholar
  520. 520.
    Madigand M, Dien J, Pavin G, et al. Encephalopathie myoclonique probablement imputable à la propafenone [letter]. Presse Med 1988; 17: 538PubMedGoogle Scholar
  521. 521.
    Jeandel C, Bannwarth B, Trechot P, et al. Encephalopathie myoclonique à la propafenone. Therapie 1990; 45: 161–2PubMedGoogle Scholar
  522. 522.
    Chua TP, Farrell T, Lipkin DP. Myoclonus associated with propafenone [letter]. BMJ 1994; 308: 113PubMedGoogle Scholar
  523. 523.
    Ghika J, Goy JJ, Naegeli C, et al. Acute reversible ataxo-myoclonic encephalopathy with flecainide therapy. Schweiz Arch Neurol Psychiatr 1994; 145: 4–6PubMedGoogle Scholar
  524. 524.
    Jeret JS, Somasundaram M, Asaikar S. Diltiazem-induced myoclonus. N Y State J Med 1992; 92: 447–8PubMedGoogle Scholar
  525. 525.
    Pedro-Botet ML, Bonal J, Caralps A. Nifedipine and myoclonic disorders [letter]. Nephron 1989; 51: 281PubMedGoogle Scholar
  526. 526.
    Lucas C, Soetaert G, Leys D, et al. Myoclonies au cours d’un traitement par buflomedil. Acta Clin Belg 1989; 44: 360–1PubMedGoogle Scholar
  527. 527.
    Uchihara T, Tsukagoshi H. Myoclonic activity associated with cefmetazole, with a review of neurotoxicity of cephalospo-rins. Clin Neurol Neurosurg 1988; 90: 369–71PubMedGoogle Scholar
  528. 528.
    New PS, Wells CE. Cerebral toxicity associated with massive intravenous penicillin therapy. Neurology 1965; 15: 1052–8Google Scholar
  529. 529.
    Cohill DF, Pezzi PJ, Greenberg SR, Frobese AS. Central nervous system toxicity secondary to massive doses of penicillin ‘G’ in the treatment of overwhelming infections. Am J Med Sci 1967; 254: 692–4PubMedGoogle Scholar
  530. 530.
    Lerner PI, Smith N, Weinstein L. Penicillin neurotoxicity. Ann N Y Acad Sci 1967; 145: 310–8PubMedGoogle Scholar
  531. 531.
    Conway N, Beck E, Somerville J. Penicillin encephalopathy. Postgrad Med J 1968; 44: 891–7PubMedGoogle Scholar
  532. 532.
    Durand JM, Telle H, Quiles N, et al. Syndrome confusionnel, myoclonies et traitement par la pefloxacine. Ann Med Interne (Paris) 1993; 144: 495–6Google Scholar
  533. 533.
    Yagi S, Moriya O, Nakajima M, et al. A case of tuberculous pleurisy associated with myoclonus and Quincke’s edema due to isoniazid and isoniazid sodium methanesulfonate. Kekkaku 1989; 64: 407–12PubMedGoogle Scholar
  534. 534.
    Fukuda T. Veratramine-induced myoclonus. Scishin Shinkeigaku Zasshi 1990; 92: 865–9Google Scholar
  535. 535.
    Bouly A, Nathan N, Feiss P. Propofol in myotonic dystrophy [letter]. Anaesthesia 1991; 46: 705PubMedGoogle Scholar
  536. 536.
    Hughes NJ, Lyons JB. Prolonged myoclonus and meningism following propofol. Can J Anaesth 1995; 42: 744–6PubMedGoogle Scholar
  537. 537.
    Mayeux R, Albert M, Jenike M. Physostigmine-induced myoclonus in Alzheimer’s disease. Neurology. 1987; 7: 345–6Google Scholar
  538. 538.
    Reutens DC, Stewart-Wynne EG. Norpethidine-induced myoclonus in a patient with renal failure [letter]. J Neurol Neurosurg Psychiatry 1989; 52: 1450–1PubMedGoogle Scholar
  539. 539.
    Sica DA, Comstock TJ. Pseudoephedrine accumulation in renal failure. Am J Med Sci 1989; 298: 261–3PubMedGoogle Scholar
  540. 540.
    Korthals JK, Gieron-Korthals MA. Eosinophilia-myalgia syndrome with myoclonic jerks. J Fla Med Assoc 1990; 77: 1031–3PubMedGoogle Scholar
  541. 541.
    Berman I, Zalma A, Durand CJ, et al. Clozapine-induced myoclonic jerks and drop attacks [letter]. J Clin Psychiatry 1992; 53: 329–30PubMedGoogle Scholar
  542. 542.
    Malow BA, Reese KB, Sato S, et al. Spectrum of EEG abnormalities during clozapine treatment. Electroencephalogr Clin Neurophysiol 1994; 91: 205–11PubMedGoogle Scholar
  543. 543.
    Meltzer HY, Ranjan R. Valproic acid treatment of clozapine-induced myoclonus [letter]. Am J Psychiatry 1994; 151: 1246–7PubMedGoogle Scholar
  544. 544.
    Bak TH, Bauer M, Schaub RT, et al. Myoclonus in patients treated with clozapine: a case series. J Clin Psychiatry 1995; 56: 418–22PubMedGoogle Scholar
  545. 545.
    Eisele G. Neurologic complications of metoclopramide therapy [letter]. N Y State J Med 1988; 88: 332PubMedGoogle Scholar
  546. 546.
    Klawans HL, Falk DK, Nausieda PA, et al. Gilles de la Tourette syndrome after long-term chlorpromazine therapy. Neurology 1978; 28: 1064–8PubMedGoogle Scholar
  547. 547.
    De Veaugh-Geiss J. Tardive Tourette syndrome. Neurology 1980; 30: 562–3Google Scholar
  548. 548.
    Stahl SM. Tardive Tourette syndrome in an autistic patient after long-term neuroleptic administration [letter]. Am J Psychiatry 1980; 30: 562–3Google Scholar
  549. 549.
    Fog R, Pakkenberg H. Theoretical and clinical aspects of the Tourette syndrome (chronic multiple tic). J Neural Transm 1980; 16 Suppl.: 211–5Google Scholar
  550. 550.
    Seeman MV, Patel J, Pyke J. Tardive dyskinesia with Tourette-like syndrome [letter]. J Clin Psychiatry 1981; 42: 357–8PubMedGoogle Scholar
  551. 551.
    Singer DW. Transient Gilles de la Tourette syndrome after chronic neuroleptic withdrawal. Dev Med Child Neurol 1981; 23: 518–30PubMedGoogle Scholar
  552. 552.
    Mueller J, Aminoff MA. Tourette-like syndrome after long-term neuroleptic drug treatment. Br J Psychiatry 1982; 141: 191–3PubMedGoogle Scholar
  553. 553.
    Klawans HL, Nausieda PA, Goetz CC, et al. Tourette-like symptoms following chronic neuroleptic therapy. Adv Neurol 1982; 35: 415–8PubMedGoogle Scholar
  554. 554.
    Jeste DV, Cutler NR, Kaufmann CA. Low-dose apomorphine and bromocriptine in neuroleptic-induced movement disorders. Biol Psychiatry 1983; 18: 1085–91PubMedGoogle Scholar
  555. 555.
    Munetz MR, Slawsky RC, Neil JF. Tardive Tourette’s syndrome treated with clonidine and mesoridazine. Psychosomatics 1985; 26: 254–7PubMedGoogle Scholar
  556. 556.
    Lal S, Al Ansari E. Tourette-like syndrome following low dose short-term neuroleptic treatment. Can J Neurol Sci 1986; 13: 125–8PubMedGoogle Scholar
  557. 557.
    Casat CD, Wilson DC III. Tics with combined thioridazine-methylphenidate therapy: case report. J Clin Psychiatry 1986; 47: 44–5PubMedGoogle Scholar
  558. 558.
    Gualtieri CT, Patterson DR. Neuroleptic-induced tics in two hyperactive children. Am J Psychiatry 1986; 143: 1176–7PubMedGoogle Scholar
  559. 559.
    Karagianis JL, Nagpurkar R. A case of Tourette syndrome developing during haloperidol treatment. Can J Psychiatry 1990; 35: 228–32PubMedGoogle Scholar
  560. 560.
    Kuniyoshi M, Inanaga K, Arikawa K, et al. A case of tardive Tourette-like syndrome. Jpn J Psychiatry Neurol 1992; 46: 67–70PubMedGoogle Scholar
  561. 561.
    Bharucha KJ, Sethi KD. Tardive tourettism after exposure to neuroleptic therapy. Mov Disord 1995; 10: 791–3PubMedGoogle Scholar
  562. 562.
    Lindenmayer JP, Da-Silva D, Buendía A, et al. Tic-like syndrome after treatment with clozapine [letter]. Am J Psychiatry 1995; 152: 649PubMedGoogle Scholar
  563. 563.
    Weinstein D, See RE, Ellison G. Delayed appearance of facial tics following chronic fluphenazine administration to guinea pigs. Pharmacol Biochem Behav 1989; 32: 1057–60PubMedGoogle Scholar
  564. 564.
    Factor SA, Sánchez-Ramos JR, Weiner WJ. Cocaine and Tourette’s syndrome [letter]. Ann Neurol 1988; 23: 423–4PubMedGoogle Scholar
  565. 565.
    Pascual-Leone A, Dhuna A. Cocaine-associated multifocal tics. Neurology 1990; 40: 999–1000PubMedGoogle Scholar
  566. 566.
    Attig E, Amyot R, Botez T. Cocaine-induced chronic tics [letter]. J Neurol Neurosurg Psychiatry 1994; 57: 1143–4PubMedGoogle Scholar
  567. 567.
    Golden GS. The relationship between stimulant medication and tics. Pediatr Ann 1988; 17: 405–6PubMedGoogle Scholar
  568. 568.
    Sverd J, Gadow KD, Paolicelli LM. Methylphenidate treatment of attention-deficit hyperactivity disorder in boys with Tourette’s syndrome. J Am Acad Child Adolesc Psychiatry 1989; 28: 574–9PubMedGoogle Scholar
  569. 569.
    Chandler ML, Barnhill JL, Gualtieri CT, et al. Tryptophan antagonism of stimulant-induced tics. J Clin Psychopharmacol 1989; 9: 69–70PubMedGoogle Scholar
  570. 570.
    Stevenson RD, Wolraich ML. Stimulant medication therapy in the treatment of children with attention deficit hyperactivity disorder. Pediatr Clin North Am 1989; 6: 1183–97Google Scholar
  571. 571.
    Borcherding BG, Keysor CS, Rapoport JL, et al. Motor/vocal tics and compulsive behaviors on stimulant drugs: is there a common vulnerability? Psychiatry Res 1990; 33: 83–94PubMedGoogle Scholar
  572. 572.
    Lipkin PH, Goldstein IJ, Adesman AR. Tics and dyskinesias associated with stimulant treatment in attention-deficit hyperactivity disorder. Arch Pediatr Adolesc Med 1994; 148: 859–61PubMedGoogle Scholar
  573. 573.
    Bruun R, Kurlan R. Opiate therapy and self-harming behavior in Tourette’s syndrome. Mov Disord 1991; 6: 184–5PubMedGoogle Scholar
  574. 574.
    Lichter D, Majumdar L, Kurlan R. Opiate withdrawal unmasks Tourette’s syndrome. Clin Neuropharmacol 1988; 11: 559–64PubMedGoogle Scholar
  575. 575.
    Sandyk R. Naloxone withdrawal exacerbates Tourette syndrome. J Clin Psychopharmacol 1986; 6: 58–9PubMedGoogle Scholar
  576. 576.
    Sandyk R: Phenobarbital-induced Tourette-like symptoms. Pediatr Neurol 1986; 2: 54–5PubMedGoogle Scholar
  577. 577.
    Burd L, Kerbeshian J, Fisher W, et al. Anticonvulsant medications: an iatrogenic cause of tic disorders. Can J Psychiatry 1986; 31: 419–23PubMedGoogle Scholar
  578. 578.
    Kurlan R, Kersun J, Behr J, et al. Carbamazepine-induced tics. Clin Neuropharmacol 1989; 12: 298–302PubMedGoogle Scholar
  579. 579.
    Robertson PL, Garofalo EA, Silverstein FS, et al. Carbamazepine-induced tics. Epilepsia 1993; 34: 965–8PubMedGoogle Scholar
  580. 580.
    Gillman MA, Sandyk R. Clonazepam-induced Tourette syndrome in a subject with hyperexplexia. Postgrad Med J 1987; 63: 311–2PubMedGoogle Scholar
  581. 581.
    Eisenhauer G, Jermain DM. Fluoxetine and tics in an adolescent. Ann Pharmacother 1993; 27: 725–6PubMedGoogle Scholar
  582. 582.
    Cunningham M, Cunningham K, Lydiard RB. Eye tics and subjective hearing impairment during fluoxetine therapy [letter]. Am J Psychiatry 1990; 147: 947–8PubMedGoogle Scholar
  583. 583.
    Shale H, Fahn S, Mayeux R. Tics in a patient with Parkinson’s disease. Mov Disord 1986; 1: 79–83PubMedGoogle Scholar
  584. 584.
    Lang AE. Akathisia and the restless legs syndrome. In: Jankovic J, Tolosa E, editors. Parkinson’s disease and movement disorders, 2nd ed. Baltimore: Williams & Wilkins: 399-418Google Scholar
  585. 585.
    Sandyk R, Kay SR. Relationship of neuroleptic-induced akathisia to drug-induced parkinsonism. Ital J Neurol Sci 1990; 11: 439–42PubMedGoogle Scholar
  586. 586.
    Barnes TR, Halstead SM, Little PW. Relationship between iron status and chronic akathisia in an in-patient population with chronic schizophrenia. Br J Psychiatry 1992; 161: 791–6PubMedGoogle Scholar
  587. 587.
    Berardi D, Zanfini R, Alessi S, et al. Effetti disforizzanti dei neurolettici in pazienti non schizofrenici. Minerva Psichiatr 1993; 34: 125–33PubMedGoogle Scholar
  588. 588.
    Sachdev P, Kruk J. Clinical characteristics and predisposing factors in acute drug-induced akathisia. Arch Gen Psychiatry 1994; 51: 963–74PubMedGoogle Scholar
  589. 589.
    Sachdev P. The epidemiology of drug-induced akathisia: Part I. Acute akathisia. Schizophr Bull 1995; 21: 431–49PubMedGoogle Scholar
  590. 590.
    Sachdev P. The epidemiology of drug-induced akathisia: Part II. Chronic, tardive, and withdrawal akathisias. Schizophr Bull 1995; 21: 451–61PubMedGoogle Scholar
  591. 591.
    Cohen BM, Keck PE, Satlin A, et al. Prevalence and severity of akathisia in patients on clozapine. Biol Psychiatry 1991; 29: 1215–9PubMedGoogle Scholar
  592. 592.
    Fagan D, Scott DB, Mitchell M, et al. Effects of remoxipride on measures of psychological performance in healthy volunteers. Psychopharmacology (Berl) 1991; 105: 225–9Google Scholar
  593. 593.
    Safferman AZ, Lieberman JA, Pollack S, et al. Akathisia and clozapine treatment. J Clin Psychopharmacol 1993; 13: 286–7PubMedGoogle Scholar
  594. 594.
    Friedman JH. Akathisia with clozapine [letter]. Biol Psychiatry 1993; 33: 852–3PubMedGoogle Scholar
  595. 595.
    Chengappa KN, Shelton MD, Baker RW, et al. The prevalence of akathisia in patients receiving stable doses of clozapine. J Clin Psychiatry 1994; 55: 142–5PubMedGoogle Scholar
  596. 596.
    Byerly MJ, Greer RA, Evans DL. Behavioral stimulation associated with risperidone initiation [letter]. Am J Psychiatry 1995; 152: 1096–7PubMedGoogle Scholar
  597. 597.
    Ward NG. Akathisia associated with droperidol during epidural anesthesia. Anesthesiology 1989; 71: 786–7PubMedGoogle Scholar
  598. 598.
    Athanassiadis C, Karamanis A. Akathisia after long-term epidural use of droperidol: a case report. Pain 1992; 50: 203–4PubMedGoogle Scholar
  599. 599.
    Hamilton PA. Metoclopramide-induced akathisia. Mil Med 1987; 152: 585–6PubMedGoogle Scholar
  600. 600.
    Sorbe B, Hallen C. Antiemetic treatment of chemotherapy-induced nausea in ovarian carcinoma patients. Gynecol Oncol 1989; 34: 141–4PubMedGoogle Scholar
  601. 601.
    Beightol RW, Coupai JJ, Shih WJ. Prevention of metoclopramide-induced akathisia during gastric emptying imaging. J Nucl Med 1991; 32: 1644–5PubMedGoogle Scholar
  602. 602.
    Cory DA. Adverse reaction to metoclopramide during enteroclysis [letter]. Am J Roentgenol 1994; 163: 480Google Scholar
  603. 603.
    Fleishman SB, Lavin MR, Sattler M, et al. Antiemetic-induced akathisia in cancer patients receiving chemotherapy. Am J Psychiatry 1994; 151: 763–5PubMedGoogle Scholar
  604. 604.
    Weimer S. Akathisia in a cancer patient treated with antiemetics [letter]. Am J Psychiatry 1995; 152: 960–1PubMedGoogle Scholar
  605. 605.
    Lipinski Jr JF, Mallya G, Zimmerman P, et al. Fluoxetine-in-duced akathisia: clinical and theoretical implications. J Clin Psychiatry 1989; 50: 339–42PubMedGoogle Scholar
  606. 606.
    Maany I, Dhopesh V. Akathisia and fluoxetine. J Clin Psychiatry 1990; 51: 210–2PubMedGoogle Scholar
  607. 607.
    Friedman EH. Fluoxetine-induced akathisia in male OCD patients [letter]. J Clin Psychiatry 1990; 51: 212PubMedGoogle Scholar
  608. 608.
    Rothschild AJ, Locke CA. Reexposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia. J Clin Psychiatry 1991; 52: 491–3PubMedGoogle Scholar
  609. 609.
    Fleischhacker WW. Propranolol for fluoxetine-induced akathisia [letter]. Biol Psychiatry 1991; 30: 531–2PubMedGoogle Scholar
  610. 610.
    Bertschy G, Vandel S. Fluoxetine-related indifference and akathisia. A case report. Therapie 1993; 48: 158–9PubMedGoogle Scholar
  611. 611.
    Marshall RD, Printz D, Cardenas D, et al. Adverse events in PTSD patients taking fluoxetine [letter]. Am J Psychiatry 1995; 152: 1238–9PubMedGoogle Scholar
  612. 612.
    Ketai R. Interaction between fluoxetine and neuroleptics [letter]. Am J Psychiatry 1993; 150: 836–7PubMedGoogle Scholar
  613. 613.
    Klee B, Kronig MH. Case report of probable sertraline-induced akathisia [letter]. Am J Psychiatry 1993; 150: 986–7PubMedGoogle Scholar
  614. 614.
    LaPorta LD. Sertraline-induced akathisia. J Clin Psychopharmacol 1993; 13: 219–20PubMedGoogle Scholar
  615. 615.
    Settle EC Jr. Akathisia and sertraline [letter]. J Clin Psychiatry 1993; 54: 321PubMedGoogle Scholar
  616. 616.
    Opler LA. Sertraline and akathisia [letter]. Am J Psychiatry 1994; 151: 620–1PubMedGoogle Scholar
  617. 617.
    Altshuler LL, Pierre JM, Wirshing WC, et al. Sertraline and akathisia. J Clin Psychopharmacol 1994; 14: 278–9PubMedGoogle Scholar
  618. 618.
    Phillips SD. A possible paroxetine withdrawal syndrome [letter]. Am J Psychiatry 1995; 152: 645–6PubMedGoogle Scholar
  619. 619.
    Adler LA, Angrist BM. Paroxetine and akathisia [letter]. Biol Psychiatry 1995; 37: 336–7PubMedGoogle Scholar
  620. 620.
    Klysner R, Larsen JK, Sorensen P, et al. Toxic interaction of venlafaxine and isocarboxazide [letter]. Lancet 1995; 346: 1298–9PubMedGoogle Scholar
  621. 621.
    Zubenko GS, Cohen BM, Lipinski JF Jr. Antidepressant-related akathisia. J Clin Psychopharmacol 1987; 7: 254–7PubMedGoogle Scholar
  622. 622.
    Yeragani VK, Pohl R, Balon R. Tricyclics, akathisia, and jitteriness [letter]. J Clin Psychopharmacol 1988; 8: 295PubMedGoogle Scholar
  623. 623.
    Sabaawi M, Richmond DR, Fragala MR. Akathisia in association with nortriptyline therapy. Am Fam Physician 1993; 48: 1024–6PubMedGoogle Scholar
  624. 624.
    Phillips SD, Ringo P. Phenelzine and venlafaxine interaction [letter]. Am J Psychiatry 1995; 152: 1400–1PubMedGoogle Scholar
  625. 625.
    Gillman PK. Possible serotonin syndrome with moclobemide and pethidine [letter]. Med J Aust 1995; 162: 554PubMedGoogle Scholar
  626. 626.
    Bakchine S, Lacomblez L, Soubrie C. Syndrome extrapyramidal au cours d’un traitement par la flunarizine. Rev Neurol (Paris) 1988; 144: 833–4Google Scholar
  627. 627.
    Rodríguez-García JL, Arechaga-Uriarte S. Akatisia inducida por flunarizina [letter]. Rev Clin Esp 1991; 188: 384PubMedGoogle Scholar
  628. 628.
    Price WA, Zimmer B. Lithium-induced akathisia [letter]. J Clin Psychiatry 1987; 48: 81PubMedGoogle Scholar
  629. 629.
    Patterson JF. Lithium-induced akathisia [letter]. J Clin Psychopharmacol 1988; 8: 445PubMedGoogle Scholar
  630. 630.
    Patterson JF. Akathisia associated with buspirone. J Clin Psychopharmacol 1988; 8: 296–7PubMedGoogle Scholar
  631. 631.
    Lawrence K. Reversal of midazolam sedation. Crit Care Med 1993; 21: 1407–8PubMedGoogle Scholar
  632. 632.
    Honan VJ. Paradoxical reaction to midazolam and control with flumazenil. Gastrointest Endosc 1994; 40: 86–8PubMedGoogle Scholar
  633. 633.
    Hollman GA. Oral midazolam and emergence delirium. Ann Emerg Med 1995; 25: 853–4PubMedGoogle Scholar
  634. 634.
    Yassa R, Groulx B. Lorazepam in the treatment of lithium-induced akathisia. J Clin Psychopharmacol 1989; 9: 70–1PubMedGoogle Scholar
  635. 635.
    Phelps SJ, Baldree LA, Boucher BA, et al. Neuropsychiatric toxicity of phenytoin. Importance of monitoring phenytoin levels. Clin Pediatr (Phila) 1993; 32: 107–10Google Scholar
  636. 636.
    Riche H, Salord F, Jourdan C, et al. Neurological side effects related to valproate after neurosurgery [letter]. Acta Neu-rochir (Wien) 1994; 127:240Google Scholar
  637. 637.
    Bernick C. Methysergide-induced akathisia. Clin Neuropharmacol 1988; 11: 87–9PubMedGoogle Scholar
  638. 638.
    Brown KW, Glen SE, White T. Low serum iron status and akathisia. Lancet 1987; I: 1234–6Google Scholar
  639. 639.
    Barton A, Bowie J, Ebmeier K. Low plasma iron status and akathisia. J Neurol Neurosurg Psychiatry 1990; 53: 671–4PubMedGoogle Scholar
  640. 640.
    O’Loughlin V, Dickie AC, Ebmeier KP. Serum iron and trans-ferrin in acute neuroleptic-induced akathisia [letter]. J Neurol Neurosurg Psychiatry 1991; 54: 363–4PubMedGoogle Scholar
  641. 641.
    Horiguchi J. Low serum iron in patients with neuroleptic-induced akathisia and dystonia under antipsychotic drug treatment. Acta Psychiatr Scand 1991; 84: 301–3PubMedGoogle Scholar
  642. 642.
    Sachdev P, Loneragan C. Acute drug-induced akathisia is not associated with low serum iron status. Psychopharmacology (Berl) 1991; 103: 138–9Google Scholar
  643. 643.
    Soni SD, Tench D, Routledge RC. Serum iron abnormalities in neuroleptic-induced akathisia in schizophrenic patients. Br J Psychiatry 1993; 163: 669–72PubMedGoogle Scholar

Copyright information

© Adis International Limited 1997

Authors and Affiliations

  • Félix Javier Jiménez-Jiménez
    • 1
  • Pedro José García-Ruiz
    • 2
  • José Antonio Molina
    • 3
  1. 1.Department of Neurology of Hospital Universitario ‘Príncipe de Asturias’Alcalá de HenaresMadridSpain
  2. 2.Department of Neurology of Fundación Jiménez DíazMadridSpain
  3. 3.Department of Neurology of Hospital Universitario Doce de OctubreMadridSpain

Personalised recommendations